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ABSTRACT 
 
The use of honey for therapeutic applications against a wide range of ailments has been 
demonstrated since the primordial age. Although modern-day medicine has advanced to 
substantial heights, there are still major concerns with drugs such as antimicrobials due to 
the ever growing problem of drug resistance. Presently, antimicrobial resistance is rife in 
South Africa (SA), where apart from common pathogens developing resistance, instances of 
extreme drug-resistant tuberculosis are dominating headlines. Complementary and 
alternative medication (CAM) such as honey has become a popular alternative, as patients 
often perceive that these ‘natural’ preparations are superior to conventional medicine with a 
lower incidence of adverse reactions subsequently resulting in the increased utilisation of 
CAM preparations.  
The aim of this study was to validate the antimicrobial efficacy of SA honey against 
pathogens associated with wound infections. Prior to this evaluation, an extensive review 
into wound pathology, conventional antimicrobial wound dressings and honey’s antimicrobial 
potential was conducted to provide an appropriate background to this study. Evaluation of 
the potential antimicrobial properties of the various SA honeys from varying geographical 
locations within the country against a variety of common wound pathogens was determined 
in vitro. Antimicrobial activity was gauged by determining minumum inhibitory concentrations 
(MICs) by the agar dilution method. Commercially available Manuka honey was utilised as a 
control and antimicrobial activity of these samples ranged from 15.28-41.67%. The mean 
MICs of the SA honey samples tested ranged from 10.42-50.00% with honey sample 16-
(FYNBOS/WC) displaying the most desirable antimicrobial activity with a mean MIC of 
10.42±8.27%.  
 
Combination studies using selected honey samples having highest antimicrobial efficacy, 
with conventional antimicrobials such as ciprofloxacin, gentamicin and antifungal agents 
such as amphotericin B and nystatin, were performed. This was conducted to investigate 
whether the phenomena of synergism, additive or antagonistic effects were observed. Honey 
displayed noteworthy potential to be combined with antibiotics namely; ciprofloxacin and 
gentamicin and antifungals namely; nystatin to produce synergism. Synergism of 16-
(FYNBOS/WC), 18-(MIXEDGUM/FS), 19-(CITYMIX/FS), 26-(FYNBOS/WC) and 41-
(INDIGENOUS/WC) with gentamicin against Stapyhlococcus aureus (S. aureus) was most 
noticeable, displaying a sum of fractional inhibitory concentration (ΣFIC) of 0.27.  
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The physicochemical properties of selected SA honeys were further investigated with 
emphasis being placed on water content, sugar content and pH and how these particular 
properties affected its antimicrobial efficacy. Furthermore, levels of impurification of honey 
were also investigated. The pH of honey samples tested in this study ranged from 3.89 to 
5.09, displaying acidic characteristics. The sugar content range was 77.00-82.50%, and the 
moisture content range was 15.80-21.60%. The percentage impurification ranged from 0.19-
33.60% with 3 samples; [1–(CITYMIXA/EC), 47-(SALIGNAGUM/KZN) and 53-(LITCHI/MP)] 
demonstrating impurification that should further be investigated. No definite correlation was 
established between these physicochemical properties and the antimicrobial activity of 
honey.  
The positive ramifications of this study formed a basis for expanding honey-based 
antimicrobial treatment against certain infectious diseases such as those affecting the skin. 
The study proved that harnessing the antimicrobial potential of SA honey could lead to 
positive outcomes especially in the SA setting from which these samples were derived.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background to this study 
 
There has been an increase in the consumer use of complementary and alternate medicines 
(CAM) as this form of pharmacotherapy is perceived to be superior by patients. Furthermore, 
it is documented that a large number of South Africans (approximately 70%) use CAM to 
initiate therapy. Possible reasons for a more natural treatment regimen include reduction of 
undesirable side effects of conventional medications. Patients perceive that CAM is 
associated with minimal side effects when compared to conventional medication (Kumari et 
al., 2009). In addition, the cost implications may also be a strong motivator (Debas et al., 
2006). The increased scientific need and consumer use of CAM has subsequently led to a 
resurgence in using these agents for medical ailments. 
 
The continuous use of antibiotics in clinical practice has consequently resulted in the 
development of multiple antibiotic resistance among bacteria. This has resulted in scientific 
efforts to discover alternative therapeutic agents (Tan et al., 2009). Clinical studies and 
research have demonstrated the effectiveness of honey’s therapeutic potential in treating 
wound infections. Honey has been utilised therapeutically since ancient times for a wide 
range of treatments related to infectious diseases. These include respiratory disorders, 
gastrointestinal disorders and infective conjunctivitis and more frequently for the treatment of 
wound infections (Molan, 1999 (a); Al-Waili, 2004; Basualdo et al., 2007; Tan et al., 2009).  
Famous ancient physicians such as Aristotle (384-322 BC) and Dioscorides (c.50 AD) 
commonly used honey as a dressing for wounds and ulcers (Molan, 1999 (b)). Honey has 
also been documented for its use in fatigue, sore throats, earache, toothache and vertigo 
(Molan, 1999 (b), Meda et al., 2004). Of particular interest is the fact that honey has 
demonstrated in vitro antimicrobial activity (Anyanwu, 2012; Moussa et al., 2012; Shenoy et 
al., 2012). Furthermore, various clinical studies have confirmed honey’s capacity as an 
effective wound healing agent (Visavadia et al., 2006). 
 
In particular, Manuka honey shows significant antimicrobial activity against various wound 
organisms as well as antibiotic resistant bacteria including methicillin-resistant 
Staphylococcus aureus (MRSA) (Visavadia et al., 2006; Mandal et al., 2010). Currently in 
Australia and New Zealand, Medihoney® and Manuka honey are marketed as therapeutic 
honeys suitable for use in ulcers, infected wounds and burns. Multifarious contemporary 
research has indicated that both these honeys, derived from the Leptospermum spp., have 
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significant antibacterial activity (Kwakman and Zaat, 2012; Kronda et al., 2013; Muller et al., 
2013).  
 
1.2 Wound pathology  
 
The purpose of this study was to primarily investigate the antimicrobial impact of honey on 
pathogens associated with wounds. It was thus imperative to understand the fundamentals 
of wound infection and healing before embarking on the analysis of honey as an antiinfective 
wound healing agent. 
 
The role of the skin as a significant barrier between the host and the environment cannot be 
overestimated as it protects the underlying tissue from becoming colonised and invaded by 
potential pathogens (Bowler et al., 2001). A wound is caused by the loss of skin integrity 
resulting in the exposure of subcutaneous tissue. Types of wounds vary and include; 
traumatic wounds, surgical wounds, burns and chronic wounds. There is an increased 
susceptibility to infection after the occurrence of a wound, and this is dependent on the 
access of pathogens and the immunocompetency status of the individual. A wound provides 
an environment which is conducive to microbial colonisation and subsequent infection as it is 
an ideal medium for a wide variety of micro-organisms. Wound contaminants are likely to 
originate from three sources. The environment can be an exogenous source as a result of 
micro-organisms in the air or from trauma. Endogenous sources usually involve mucous 
membranes (primarily the gastrointestinal, oropharyngeal and genitourinary membranes), 
and lastly contaminants can arise from normal skin microflora. Infection occurs when these 
contaminants, that are continuously multiplying, overwhelm the body’s immune system 
resulting in inflammation and active disease. This, in turn, inhibits the healing of the wound. 
In severe infections, the contaminants may enter the bloodstream causing septicaemia 
which can result in organ failure and death (Bowler et al., 2001; Patel, 2007). Figure 1.1 is a 
typical illustration of a wound, which can be infected with a number of polymicrobial 
contaminants such as Staphylococcus epidermidis, Corynebacterium spp., 
Proprionibacterium spp., Pityrosporum spp., Staphylococcus aureus, Beta-hemolytic 
Streptococcus, Escherichia coli, Proteus spp., Klebsiella spp., Pseudomonas spp., 
Acinetobacter spp., which may result in septicaemia. The inflammatory response is also 
demonstrated. 
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Figure 1.1: Illustration of a typical wound, the inflammatory reaction and the overwhelming 
contaminants resulting in septicaemia, [Adapted and modified from Dr D. Honardoust (The 
Canadian Association of Medical Spas and Aesthetic Surgeons). 
http://www.camacs.ca/Directors.php, accessed 20th December 2012]. 
 
Wounds have become a clinical concern and alternate agents could be beneficial. Honey 
has therapeutic properties as mentioned previously and research demonstrates its potential 
as a therapeutic agent especially in wound management. Silver sulfadiazine and mupirocin 
are antimicrobial agents conventionally utilised in the management of burns and wounds. A 
major shortcoming of topical antimicrobial agents is the fact that they increase the risk of 
developing antimicrobial resistant organisms (Ovington and Eisenbud, 2004).  
 
Wound healing revolves around the body’s replacement of injured tissue with healthy living 
tissue. The goals of wound therapy and management include; rapid wound closure and an 
aesthetically acceptable scar. Ideally, wound dressings should possess traits such as; 
absorbing exudates and potential toxins from the wound surface, allowing gaseous 
exchange, providing thermal insulation to the wound, maintaining a high humidity at the 
wound/dressing interface, being non-toxic, allowing for easy removal devoid of trauma, 
possessing considerable physicomechanical strength to resist damage and tear upon 
handling, being comfortable and sterilizable and protecting the wound from bacterial 
penetration (Turner, 1979; Stashak et al., 2004; Thu et al., 2012).  
 
potential pathogens 
dermis 
mature 
neutrophil 
mast cell 
mast cell  
small blood vessel plasma 
plasma 
INJURY 
neutrophil 
epidermis 
potential pathogens 
4 
 
1.3 Conventional antimicrobial wound dressings 
Various dressings exist for both acute and chronic wounds. Hydrogel-based dressings or 
hydrocolloid dressings have formed the platform for moist wound care. Wound healing is 
generally facilitated by dressings that maintain a moist environment. Hydrocolloid dressings 
function by forming a gel upon exposure to wound exudates. Gel formation removes excess 
fluid without leading to desiccation of the wound. A shortfall of hydrocolloid dressings is its 
fluid-handling capacity which is dependent on a number of factors including the 
physicochemical properties of the dressing (Thu et al., 2012). As bacteria are rife in wound 
fluid, it is pivotal that fluid-retaining dressings absorb and retain the bacteria present 
(Wysocki et al., 2002).  
Depending on the type of wound, a drug-loaded wound dresssing such as an anti-infective 
or pain controlling dressing, may be used. These dressings are common in chronic wound 
therapy (Lawrence, 1994; Steffansen and Herping, 2008; Fouda et al., 2009). Antimicrobial 
wound dressings are utilised to minimise the number of micro-organisms. Due to the 
development of antibiotic-resistant organisms such as MRSA, vancomycin-resistant 
Enterococcus faecalis and Pseudomonas aeruginosa, there has been an increase in the use 
of antimicrobial dressings (Stashak et al., 2004). Critical colonisation of a wound leading to 
impaired wound healing necessitates the use of an antimicrobial dressing. Features of 
critical colonisation include: delayed healing, malodour, a new onset of pain and increasing 
slough even after debridement. Antimicrobial wound dressings generally contain silver, 
iodine and polyhexamethylenebiguanide (PHMB) and cover a wide range of micro-
organisms including Pseudomonas aeruginosa and Staphylococcus aureus (Abdelrahman 
and Newton, 2011).  
 
The in vitro potential of silver chloride coated nylon dressings have been effectively 
demonstrated with the dressing displaying effective antimicrobial and antifungal action. 
Pathogens tested included Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia 
coli, Klebsiella pneumoniae and Streptococcus equi subspecies zooepidemicus. The 
dressing functions by the gradual release of silver over a period of time. Release rates of 
silver vary with different dressing types. It is proposed that the best time of use is from the 
inflammatory to repair phase of wound healing (Adams et al., 1999; Stashak et al., 2004). A 
major shortfall of the use of silver is its association with tissue toxicity and impaired healing.  
 
Antimicrobial Gauze Dressing (AMD) (Kerlix®) is a gauze-based dressing containing the 
active ingredient PHMB. PHMB has a wide range of antimicrobial activity. The 
biocompatibility of the dressing is far more superior to chlorhexidine-based dressings, 
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reduces bacterial penetration into the wound and resists bacterial colonisation within the 
dressing itself. The dressing is best applied during the inflammation and debridement 
phases of the healing process. It is particularly advantageous in wounds with rife bacterial 
activity and an open synovial cavity. In addition, the dressing aids in drainage of the wound 
(Angelique and Rodeheaver, 2001; Stashak et al., 2004).  
 
Iodine-based wound dressings synthesised from crosslinked polymerised dextran have been 
studied. Hydration of the dressing subsequently results in the release of iodine which has an 
antimicrobial effect and may interact with macrophages to indirectly facilitate wound healing. 
It is most efficacious in the early inflammatory and repair phases of wound healing. Similar 
studies have established iodine as a broad-spectrum antimicrobial with fungicidal activity 
(Moore et al., 1997; Hotoson-Moore, 2003). 
 
Antibiotic-Impregnated Collagen Sponges (AICS) are of particular importance in 
orthopaedics and soft tissue surgery. They basically consist of a collagen platform 
interspersed with an antibiotic agent. A prime example of an AICS is CollatampG® consisting 
of gentamicin interspersed within a Type 1 bovine collagen that is denatured. The dressing 
operates by regulating homeostasis and causes aggregation and adhesion of platelets and a 
few bridge proteins. It prevents as well as treats infection by allowing the release of 
gentamicin from the collagen matrix. This is achieved by initial passive diffusion followed by 
collagen breakdown by macrophages. Drug concentrations are highest at the site of 
dressing occlusion (Letsch et al., 1991; Stemberger et al., 1997; Summerhays, 2000).  
 
A poultice pad contains boric acid which is a mild antiseptic as well as Tragacanth which is 
the poultice agent. It is designed to fit the sole of the foot. It may be used in infected 
absecceses or dirt-infested wounds and its use may extend to other parts of the body 
(Stashak et al., 2004). 
 
Activated charcoal wound dressings serve to facilitate wound healing by creating a moist 
environment, effectively absorb bacteria, prevent exhuberant granulation tissue formation 
and deodourise wounds. Antibacterial properties are solely attributed to its ability to absorb 
the bacteria thereby reducing their numbers (Frost et al., 1980).  
 
Knill and co-workers (2004) synthesised alginated-based fibres treated with chitosan for use 
as an antibacterial wound dressing. The alginate served to absorb excess exudate and liquid 
and chitosan played a role in its antimicrobial, wound healing and haemostatic properties. In 
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addition, the chitosan was released in a slow, controlled manner providing extended 
antibacterial action (Knill et al., 2004).  
 
Table 1.1 summarises and displays the current commercially available antimicrobial wound 
dressings in terms of their trade names, the active antimicrobial agent, the type of dressing 
supporting the active agent and the name of the manufacturers of the antimicrobial 
dressings (Zahedi et al., 2010).  
 
Table 1.1: Commercially available antimicrobial dressings, [Adapted from Zahedi et al., 
2010]. 
DRESSING NAME ANTIMICROBIAL 
INGREDIENT 
DRESSING 
FORMAT 
MANUFACTURER 
Acticoat absorbent Ionic silver Calcium alginate Smith & Nephew, 
Inc, Largo, FL, USA 
Actisorb Silver 220 Ionic silver and 
activated charcoal 
Silver impregnated 
activated charcoal 
cloth 
Johnson and 
Johnson Wound 
Management, 
Somerville, NJ, USA 
Arglaes Ionic silver Transparent film or 
powder 
Medicine Industries, 
Inc, Mundelein, IL, 
USA 
Aquacel AG Ionic silver Hydrofiber Convatec, Skillman, 
NJ, USA 
Contreet H Ionic silver Hydrocolloid Coloplast Corp, 
Marietta, GA, USA 
Contreet F Ionic Silver Foam Coloplast Corp, 
Marietta, GA, USA 
Iodosorb Molecular iodine Gel or paste HealthPoint Ltd, Ft. 
Worth, TX, USA 
Silvasorb 
Antimicrobial Silver 
Dressing 
Ionic silver Hydrogel sheet or 
amorphous gel 
Medline Industries, 
Mundelein, IL, USA 
Kerlix AMD Gauze PHMB Gauze Tyco 
Healthcare/Kendall, 
Mansfield, MA, USA 
 
7 
 
1.4 Honey as an antimicrobial agent 
 
Investigations into the antimicrobial properties of honey from other geographical regions 
other than Southern Africa have been more substantially investigated. Studies have focused 
on a wide range of geographical regions including Dubai (Al-Waili et al., 2004), New Zealand 
(Brady et al., 2004) Australia (Lusby et al., 2005), Portugal (Henriques et al., 2005), 
Argentina (Basualdo et al., 2007), Wales (Cooper et al., 2008), Spain (Gallardo-Chacon et 
al., 2008), Iran (Khosravi et al.,2008), Ireland (Maeda et al., 2008) India (Mandal et al., 
2010), Pakistan (Gulfraz et al., 2010), Chile (Sherlock et al., 2010), Cuba (Alvarez-Suarez et 
al., 2010) Malaysia (Khoo et al., 2010) Greece (Voidaroua et al, 2011), Algeria (Moussa et 
al., 2012), and Nigeria (Anyanwu, 2012) to name only a few. These studies provide an 
important global perspective as it is evident that the antimicrobial activity of honey varies 
according to their composition which in turn is dependent on geographical location, botanical 
origin, bee species, season, and its treatment since harvest including storage (Kaskoniene 
and Venskutonis, 2010). Furthermore, not all honeys are equally effective for wound healing 
as the antimicrobial activities of honey can demonstrate 100-fold variances (Sherlock et al., 
2010). 
 
A search using the keywords “honey as an antimicrobial” was performed utilising the 
renowned scientific database, ScienceDirect and was conducted to view results each year 
for the past 10 years until present day (November, 2013). The number of articles, each year, 
for the last 10 years is illustrated in Figure 1.2. The search summarises the vast world-wide 
data confirming honeys ability as a potential antimicrobial agent as well as the demonstration 
that honey research is escalating. In the last ten years, honey research has increased four-
fold. 
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Figure 1.2 : Number of articles appearing on a ScienceDirect search using the key 
words “honey as an antimicrobial”, per year, over the last 10 years.  
Various honey types have been studied as potential antimicrobial agents and a brief review 
of selected articles is outlined in Table 1.2. The table summarises only a proportion of the 
global perspective of honey research where the geographical region in which the honey(s) 
were harvested, the microbiological assay utilised, the tested pathogens and a brief 
summary of the results was obtained.  
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Table 1.2: Global antimicrobial research performed on honey. 
GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
Cuba Agar dilution 
method 
S. aureus, P. aeruginosa, B. 
subtilis, E. coli 
Most sensitive micro-organism was S. aureus 
followed by P. aeruginosa, B. subtilis  and E. 
coli were moderately sensitive to the antimicrobial 
activity of honey. In general, the Gram-positive 
bacteria were more sensitive than the Gram-negative 
bacteria. 
Alvarez-
Suarez et al., 
2010 
Portugal Agar streak 
dilution 
B. subtilis, S. aureus, S. 
lentus, P. aeruginosa, K. 
pneumoniae and E. coli 
 S. aureus was the most sensitive strain and B. 
subtilis, S. lentus, K. pneumoniae and E. coli were 
moderately sensitive. P. aeruginosa displayed a lack 
of antimicrobial activity. 
Estevinho et 
al., 2008 
Greece Agar well 
diffusion 
S. aureus, E. coli, S. 
typhimurium, S. pyogenes,  B. 
cereus,  B. subtilis 
Highest activity of 17.4 and 19.2% (w/v) was exhibited 
for coniferous and thyme honeys respectively. This 
was followed by citrus and polyfloral honeys with 
20.8 and 23.8% respectively.  
Voidaroua et 
al., 2011 
Ireland Broth dilution  MRSA Honey was able to reduce the cultural count of all 
CA-MRSA from approximately 106 colony-forming 
units (CFUs) (mean=6.46 log10 CFU/g) to none 
detectable within 24 hours. 
Maeda, et al., 
2008 
India, UK and New 
Zealand 
Agar dilution E. coli , P. aeruginosa and S. 
enterica serovar Typhi 
The bactericidal activity of honey was demonstrated 
at 3% (v/v) for S. enterica serovar Typhi and E. Coli 
and at 3.5% (v/v) for P. aeruginosa. 
Mandal, et al., 
2010 
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GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
Algeria Disc diffusion 
and well 
methods 
S. aureus, S. pyogenes The MIC% for S. aureus and S. pyogenes ranged 
from 12-95% and 25-73% respectively. 
Moussa et al., 
2012 
Australia Agar dilution 
method 
C. albicans, E. coli, 
Enterobacter aerogenes, K. 
pneumoniae, M. phlei, S. 
california, S. enteritidis, S. 
typhimurium, S. marcescens, 
S. sonnei, S. aureus and S. 
epidermidis. 
All honeys inhibited 12 of the 13 bacteria tested with 
only S. marcescens and C. albicans not inhibited. 
Although Medihoney® and Manuka honey had the 
overall best activity, the locally produced honeys had 
equivalent inhibitory activity for some of the bacteria. 
Lusby et al., 
2005 
Argentina 
 
 
Agar well 
diffusion 
 
 
S. aureus, S. epidermidis, M. 
luteus, S. uberis, E. 
faecalis, P. aeruginosa, E. coli, 
and K. pneumonia. 
 
S. aureus and S. epidermidis was inhibited by the 
majority of the undiluted honeys. Some honey 
samples provided by apiarists also inhibited the 
growth of S. aureus even at 50% dilution. 
 
Basualdo et 
al., 2007 
 
New Zealand Agar well 
diffusion 
58 strains of S. aureus were 
tested 
MICs ranged from 2-3% (v/v) for Manuka honey  
and 3-4% (v/v) for pasture honey. 
Cooper et al., 
1999 
Costa Rica Agar well 
diffusion 
P.  aeruginosa, S. aureus, S. 
cerevisiae, C. albicans and B. 
cereus 
The activity of honey produced by Apis mellifera and 
T. angustula was similar. In addition, the 
susceptibility of yeasts to honey of either species 
was greater than that of bacteria. 
Demera and 
Angert, 2004 
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GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
Malaysia Broth dilution  S. pyogenes, coagulase-
negative Staphylococci, 
MRSA, S. agalactiae  and S. 
aureus, S. maltophilia, A. 
baumannii, S. enterica serovar 
typhi, P. aeruginosa, P. 
mirabilis, S. flexneri, E. coli 
and E. cloacae 
Tualang honey displayed MICs ranging from 8.75 - 
25% when compared to Manuka honey with MICs 
ranging from 8.75-20%.  
Tan et al., 
2009  
New Zealand Agar 
incorporation 
(dilution) 
technique 
Coagulase-negative 
Staphylococci 
Inhibitory action at dilutions of 3.6 ± 0.7% (v/v) for the 
pasture honey and 3.4 ± 0.5% (v/v) for the Manuka 
honey 
French et al., 
2005 
UAE Broth dilution E. coli, E. cloacae, P. 
aeruginosa, S. dysenteriae, 
Klebsiella spp., H. influenzae, 
Proteus spp., S. aureus, S. 
hemolyticus group B, and C. 
albicans 
Growth of all the isolates was completely inhibited at 
honey concentrations ranging from 30–100% with 
the most sensitive microbes being E. coli, P. 
aeruginosa, and H. influenzae.  
Al-Waili, 2004 
Nigeria Agar well 
diffusion 
A. niger, A. flavus, P. 
chrysogenum, M. gypseum, C. 
albicans and Saccharomyces 
spp. 
The most sensitive of all the fungal isolates studied 
was M. gypseum, while C. albicans was the least 
sensitive. The MIC and Minimum Fungicidal 
Concentration (MFC) values for the honeys ranged 
between 12.5-50% (v/v). 
Anyanwu, 
2012 
Australia Phenol 
equivalence 
assay (disc 
diffusion and 
well methods) 
S. aureus Exemplary activity was seen in samples derived from 
marri (Corymbia calophylla), jarrah (Eucalyptus 
marginata) and jellybush (Leptospermum 
polygalifolium).   
Irish et al., 
2011 
Iraq Disc diffusion 
method 
S. aureus, E. coli and P. 
aeruginosa 
Inhibitory effects in vitro at concentrations of 50, 75 
and 100%.  
 
Al-Naama, 
2009 
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GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
New Zealand, 
Chile 
Agar well 
diffusion 
MRSA, E. coli and P. 
aeruginosa 
Ulmo 90 honey displayed a greater antibacterial 
activity (MIC 3.1%-6.3% v/v) against all MRSA 
isolates tested and similar activity against E. coli and 
P. aeruginosa than Manuka honey (12.5% v/v).  
Sherlock et al., 
2010 
Nigeria Agar well 
diffusion 
S.  aureus, P. aeruginosa, K. 
pneumoniae, B. subtilis and E. 
coli 
Inhibition of growth of the test organisms being 
achieved between 25-100% (w/v).   
Osho and 
Bello, 2010 
Czech Republic Agar dilution 
Method 
L. monocytogenes, S. 
aureus, E. coli and S. 
typhimurium 
Honey produced in the Czech Republic is 
antimicrobially effective with the highest and most 
significant effect in honeydew honeys. 
Vorlova et al., 
2005 
Egypt Agar well 
diffusion 
P. aeruginosa, E. coli, K. 
pneumoniae, K. oxytoca, B. 
cereus, B. subtlis, B. pumilus, 
B. brochiseptica and M. luteus 
Undiluted honey samples displayed antimicrobial 
activity at 75%, 50%, 30% and 10% across all 
pathogens tested. Variations in antimicrobial activity 
were attributed to the phenolics; ferulic acid and 
pinobanksin isolated. 
Hamouda and 
Marzouk, 2011 
Algeria Disc and well 
diffusion 
methods, 
spectrophotom
etric assay 
E. coli and P. aeruginosa Zone of inhibition diameter for tested honey for P. 
aeruginosa and E. coli was 0-30 mm and 0-38 mm, 
respectively. The MIC ranged from 90-91% and 56-
96% for the respective organisms.  
Moussa et al., 
2012 
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GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
Iran Microdilution 
broth method 
C. albicans, C. parapsilosis, C. 
tropicalis, C. kefyr, C. glabrata, 
C. dubliniensis 
C. albicans growth was stunted by increasing honey 
concentrations. The highest inhibitory effect of 
different honeys was reported in C. tropicalis, C. 
glabrata and C. dubliniensis. All honeys were able to 
produce complete inhibition of candidal growth with 
MFC ranging from 29-56 %.  
Khosravi et al., 
2008 
Wales Agar well 
diffusion 
S. aureus The total and non-peroxide activity of Manuka honey, 
was equivalent to 18.5% (w/v) phenol. 71 of the 
Welsh samples possessed a 6.9% w/v highest phenol 
equivalent. 
Cooper et al., 
2010 
New Zealand Agar well 
diffusion 
S. aureus, C. albicans, E. coli, 
T. mentagrophytes 
Antibacterial activity against S. aureus was 
demonstrated by half of the samples tested with 
activity ranging from 5.0-27.9% phenol equivalent. 
Antibacterial activity against E. coli was evident in 
approximately 30% of the samples tested. Despite 
this, honey concentrations required for 
inhibition were in excess of 19%, with a single 
exception. Similarly, antifungal activity was observed 
in 35% of samples although the levels of activity 
measured were low. 
Brady et al., 
2004 
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GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
Pakistan Agar well 
diffusion 
S. aureus, E. coli, C. albicans 
and A. niger 
The growth of bacteria, yeast and fungi were 
significantly inhibited by Acacia and Citrus honey.  
Undiluted or 100% honey proved to be the most 
suitable for the inhibition of growth of pathogenic 
organisms.  
Gulfraz et al., 
2010 
India Agar dilution 
method 
P.  aeruginosa All the strains of P. aeruginosa were found to be 
sensitive to honey at an MIC of 20%. This was 
compared to Dettol® with an MIC of 10%. Depending 
on the dilutions of the honey tested, all the isolates of 
P. aeruginosa tested were killed in 12-24 h.  
Shenoy et al., 
2012  
South Africa Agar well 
diffusion 
H. pylori  Activity against H. pylori was achieved by all the 
honeys with most activity at a concentration of 75% 
v/v. A zone of inhibition diameter of 18.0 ± 7.4 mm 
was achieved by clarithromycin, the positive control. 
This was not significantly different from honeys at 
75% v/v  and solvent extracts.  
Manyi-Loh et 
al., 2010 
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GEOGRAPHICAL 
REGION OF 
HONEY 
METHOD PATHOGENS RESULTS REFERENCE 
South Africa Broth dilution  C. albicans,  S. anginosus, S. 
oralis 
Carbohydrate concentration proved pivotal in the 
antimicrobial activity of the honeys above 25%. The 
antibacterial activity of the honeys was far superior to 
the antifungal activity of the honeys with the bacteria 
being more susceptible and the yeast, C. albicans 
more resistant. S. anginosus and S. oralis proved to 
be superiorly sensitive to the honeys than the other 
test bacteria. 
Basson and 
Grobler, 2008 
South Africa Broth dilution 
method 
C. albicans A reduction in the growth of C. albicans was 
observed with increasing honey concentrations. 
Whilst partial inhibition was demonstrated with the 
controls, bluegum and fynbos, wasbessie honey at a 
concentration of 25% demonstrated 29.4% inhibition 
on the growth of C. albicans. 
Theunissen et 
al., 2001 
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Given the global attention to this field of research, the lack of research conducted on SA 
honeys is of significant concern. SA possesses a significant floral biodiversity with many 
unique, indigenous plants. Furthermore, there are over 30 000 plant species of which the 
Cape boasts one of the most diverse temperate flora on earth which could potentially result 
in many types of unique honey with varying floral origins (Goldblatt and Manning, 2002). The 
honey industry in SA has a growing potential to produce honey of suitable quality and 
quantity, however, SA utilises approximately 2026 tons of honey annually of which only 1533 
tons are produced in SA and the balance of 493 tons is imported (Department of Water 
Affairs and Forestry, 2005). China is one of the largest global producers of honey and 
produced 402 000 tons in 2009 (Guo-xue et al., 2011). Standardisation of honey may help 
stimulate and further nurture the honey industry in SA. 
 
The antimicrobial efficacies of SA plants have been studied extensively with many promising 
antimicrobial properties (Van Vuuren, 2008). Furthermore, there is in excess of a 100 nectar 
and pollen producing plants in South Africa, all of which contribute significantly to honey 
production. At least 38 of these species are indigenous (Anderson et al., 1983). Bearing this 
in mind, there is the potential that some honeys may have superior or similar antimicrobial 
properties to the well marketed Manuka honey which is a Leptospermum-derived honey. 
Other Leptospermum-derived honeys include; Medihoney®, a therapeutic honey suitable for 
use in ulcers, infected wounds and burns currently marketed in Australia. 
 
Research has indicated that these honeys, have significant antimicrobial activity against 
various wound organisms as well as antibiotic resistant bacteria (Brady et al., 2004). Despite 
this, relevant searches on globally accepted scientific databases Scopus, ScienceDirect and 
PubMed (search date - November 2013), reveal limited studies involving the antimicrobial 
investigations of SA honeys (Theunissen et al., 2001; Basson and Grobler, 2008; Manyi-loh 
et al., 2010; Manyi-loh et al., 2012) have been undertaken.  
 
Manyi-loh and co-workers (2010) investigated the activity of commercially purchased 
honeys, Goldcrest, Pure Honey (floral sources of Citrus limon and Citrus sinesis) and Citrus 
Blossom (floral source of berry orchards) against Helicobacter pylori. All the honeys 
demonstrated activity against H. pylori at honey concentrations of 10.00% (v/v) and greater. 
Manyi-loh and co-workers (2012) further investigated the fraction responsible for 
antibacterial activity in Goldcrest n-hexane extract. The Goldcrest mobile phase 3 fraction 
(5mg/ml) displayed the best antibacterial activity. Basson and Grobler (2008) investigated 
the activity of a variety of honeys from Eucalyptus cladocalyx (bluegum), Leucospermum 
cordifolium (pincushion), a mixture of heather shrubs mainly Erica species (fynbos) and 
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Leptospermum scoparium (Manuka honey) against a number of Streptococcus strains as 
well as Candida. albicans, Escherichia coli and Staphylococcus aureus. These honeys 
demonstrated antimicrobial activity at concentrations of 50.00% (v/v). Theunissen and co-
workers (2001) examined the antifungal activity of honey commonly found in the Western 
Cape region of SA against C. albicans. The floral types of honey investigated were 
Eucalyptus cladocalyx (bluegum), Myrica cordifolia (wasbessie) and fynbos (a mixture of 
many heather shrubs mainly derived from the botanical origin of Erica species). The study 
investigated concentrations up to 25.00% (w/w). It was demonstrated that an increased honey 
concentration resulted in a greater inhibition of C. albicans. It was also reported that Myrica 
cordifolia honey (25.00% w/w) produced the greatest inhibition against C. albicans 
(Theunissen et al., 2001).  
 
While these studies demonstrate the antimicrobial potential of SA honeys, they unfortunately 
focused on a limited number of honey samples, with little attention given to possible 
impurification. Furthermore, none of the studies took cognisance of the fact that honey has 
historically been associated with wounds and as such, pathogens associated with wound 
healing could have been given priority. With this in mind, the study presented here focused 
on 83 SA honey samples and pathogens associated with wound healing. 
 
1.5 Physicochemical properties of honey 
 
The physicochemical properties of honey contribute to its antimicrobial and wound healing 
properties. Contributing properties are osmolarity, pH, water content and hydrogen peroxide 
production. Hyperosmolar activity has both bactericidal and bacteriostatic activity and 
functions as the high solutes in the honey draws the water required for growth by the 
pathogens and cause shrinkage and destruction of the bacterial cell wall (Bangroo et al., 
2005). The enzyme glucose oxidase is incorporated into honey by the bee during nectar 
processing and is responsible for the conversion of glucose to gluconic acid and hydrogen 
peroxide upon the addition of water. Research has indicated that an acidic pH (3.2-4.5) 
contributes to antimicrobial activities (Mandal et al., 2010). The pH of honey aids in creating 
optimal conditions for fibroblast activity, allowing the migration, proliferation, and 
organisation of collagen and increases the quantity of oxygen off loaded from haemoglobin 
into the capillaries. Furthermore, the high viscosity of honey helps to provide a protective 
barrier to prevent infection (Lusby et al., 2002; Simon et al., 2009). The benefits of a moist 
environment are well recognised in wound healing, where wound repair is accelerated. The 
moist environment offered by honey protects the wound, reduces infection rates, debrides 
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necrotic tissue, promotes granulation tissue formation and is an effective analgesic (Lusby et 
al., 2005). 
 
Figure 1.3 summarises the pH conditions for optimum wound healing. In essence, a lower 
pH results in wound healing whereas an increased pH results in wound breakdown. The 
schematic emphasises the fact that a pH of near 3.5 (the pH of Medihoney®) aids in wound 
healing by significantly reducing the surface wound pH, thus increasing oxygen diffusion and 
decreasing protease activity. Medihoney® facilitates the overall wound healing process by 
promoting a moist wound environment, reducing inflammation, debriding the wound and 
stimulating the immune system.  
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Figure 1.3: The pH conditions for optimum wound healing, [Adapted from 
www.mountainside-medical.com/products/Medihoney-Honeycolloid-Dressing-with-Adhesive-
Border-10%7B47%7Dbox.html, accessed 20th January 2013]. 
 
1.6 Wound dressings containing honey 
 
An overview of wound dressings (Section 1.3) demonstrates the importance of relevant 
treatment protocols in wound management. The use of honey in wound dressings has also 
been investigated. Honey-based hydrogel dressings have also been formulated for 
enhanced wound healing (Yousof et al., 2007; Wang et al., 2012).  
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Wounds dressed with honey often show early initiation of anti-inflammatory activity and 
stimulation of immune responses (Brady et al., 2004). The proliferation of B-lymphocytes 
and T-lymphocytes, tumour necrosis factor, and interleukin factors have been demonstrated 
by honey (Molan, 2001). The anti-inflammatory action of honey reduces oedema and the 
amount of exudates produced. Re-epithelisation and growth of granulation tissue occur 
quicker resulting in quicker rates of wound healing and decreased scarring (Molan, 2006; 
Simon et al., 2009).  
 
Honey aids in the deodorisation of infected wounds. Amino acids from the serum and dead 
cells are normally metabolised by bacteria resulting in the formation of ammonia, amines 
and sulphur compounds. These compounds are generally responsible for the malodour 
associated with wounds. Honey provides a substitute to the amino acids resulting in the 
formation of lactic acid (Lusby et al., 2002). Honey is also a non-adherent dressing as the 
layer of diluted fluid and honey prevents the dressing from adhering to the wound, thus the 
dressing can be changed without disrupting the partially healed wound or causing 
tenderness to the patient.   
 
The desirable properties of honey make it an ideal marketable wound healing product, 
however, honey as with most natural products, may have a larger variance in therapeutic 
components depending on its origin. Not all honeys are equally effective for wound healing 
as the antimicrobial activities of honey can demonstrate 100-fold variances (Sherlock et al., 
2010). Honey comprises a wide range of constituents including a range of carbohydrates, 
water, amino acids, enzymes, organic acids, phenolic acids, flavonoids, pollen ash and wax 
(Henriques et al., 2005). Variations in the ratios of these constituents exist in different types 
of honey depending on botanical origin, age, season, climate and its treatment since 
harvest.  
 
Molan (2006) successfully corroborated various studies establishing honey as an effective 
antimicrobial agent especially useful in wound management (Molan, 2006). The antibacterial 
potential of honey has been demonstrated against a variety of Gram-positive and Gram- 
negative pathogens with activity extending to aerobic and anerobic organisms (Abdelmalek 
et al., 2012). The contemporary use of honey in wound dressings is an innovation that is 
fast-developing.  
 
European Patent EP1450871B1 (Bray et al., 2009) describes a formulation that is a wound 
dressing. The dressing consists of a wound contact layer containing honey (antimicrobial) 
and sodium alginate (moisture absorbing), a fabric backing layer that is water-permeable 
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and an intermediate layer, that is also water-permeable and contains honey and sodium 
alginate. A diagrammatic representation of the patented honey-based dressing is illustrated 
in Figure 1.4 and emphasises the novelty and importance of utilising honey as an 
antimicrobial agent for wound management (Bray et al., 2009).  
 
 
 
 
 
 
 
 
 
Figure 1.4: Diagrammtic representation of a honey-containing wound dressing, [Adapted 
from  Bray et al., 2009].  
 
1.7 Honey derived from Leptospermum scoparium 
 
After extensive research on many unifloral New Zealand honeys, the greatest activity was 
noted with Manuka honey derived from the native Manuka tree, Leptospermum scoparium. 
The non-peroxide antimicrobial activity of honey is found to be due to components derived 
from the floral source. It was also established that not all Manuka honeys shared the same 
antimicrobial activity and activity varied with differing localities. Manuka honey has been 
demonstrated to be effective against a wide number of pathogens including H. pylori, S. 
enterica serovar Typhi, P. aeruginosa, E. coli and MRSA (Somal et al., 1994; Maeda et al., 
2008; Mandal et al., 2010).  
 
Medical honey containing antimicrobial agents are active against a wide spectrum of 
pathogens when undiluted. Upon dilution, however, the activity of these honeys is not the 
same (Cooper and Jenkins, 2009). Methylglyoxal is a distinctive heat stable component of 
Manuka honey which allows the honey to retain its antimicrobial activity even when diluted 
with wound exudates (Mavric et al., 2008). The mechanism of antimicrobial action of Manuka 
Honey containing wound dressing 
Wound contact layer with 
remainder of honey-
sodium alginate Intermediate 
layer 
containing 
honey and 
sodium 
alginate 
Fabric backing layer 
Flexible 
adhesive fabric 
Central hole through which water vapour absorbed into the 
dressing, is able to transpire 
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honey centres around the honey’s ability to inhibit bacterial cell division and disrupt the 
bacterial cell surface, thus leading to cell lysis and death (Henriques et al., 2010; Jenkins et 
al., 2011).  
 
Honeys produced from Leptospermum spp. are commercially available as the Medihoney® 
antibacterial range of honey-based wound dressings. Medihoney® dressings are indicated for 
wounds colonised by antibiotic-resistant pathogens, locally infected wounds, chronic 
wounds, necrotic wounds, sloughy wounds, burns, donor and recipent graft sites, superficial 
wounds, surgical wounds and malodorous wounds. Although Medihoney® is absorbed by the 
body, the amount absorbed does not raise the blood sugar and hence it is safe for use by 
diabetic patients. In addition, Medihoney® is non-toxic and may be used in paediatric 
patients. Another significant advantage of Medihoney® is the fact that there are no known 
reports of bacterial resistance (Grothier and Cooper, 2011).  
 
Figure 1.5 describes the mechanism of action of Medihoney®. The wound is kept moist by 
the osmotic pull of Medihoney® drawing the lymph from the deeper tissues through the 
wound. Removal of devitalised tissue from the wound bed is facilitated by the outflow of 
lymph fluid.  
 
Figure 1.5: Mechanism of action of Medihoney® [Adapted from www.mountainside-
medical.com/products/Medihoney-Honeycolloid-Dressing-with-Adhesive-Border-
10%7B47%7Dbox.html, accessed 20th January 2013]. 
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22 
 
1.8 Honey combinations and synergy 
 
Infectious diseases impact on human health and mortality. Effective treatment of these 
diseases is becoming more difficult as a result of emerging antimicrobial resistance and the 
lack of development of new antimicrobial drugs poses a threat to healthcare. To combat 
these problems combination therapy is often practiced. Combination therapy is the gold 
standard in the treatment of many infectious diseases such as Human Immunodeficiency 
Virus (HIV) and Tuberculosis (TB). Honey is one complementary medicine that can be 
potentially synergistic with conventional antimicrobial therapies and aid in combating 
bacterial resistance. A handful of combination studies bears testament to this (Table 1.3). 
This study investigated the potential of combining SA honey with other conventional wound 
agents to produce a possible synergistic effect.  
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Table 1.3: Combination studies performed with honey and conventional antimicrobial agents. 
 
COMBINATION METHOD PATHOGEN RESULTS REFERENCE 
Manuka honey and 
oxacillin  
Disc diffusion, E 
test strips, serial 
broth dilution, 
chequer boards 
MRSA Synergism was observed between oxacillin 
and Manuka honey against  MRSA 
Jenkins and Cooper, 
2012 
Medihoney®  and 
rifampicin 
Checkerboard 
microdilution 
assays, time-kill 
curve experiments, 
agar diffusion 
MRSA Synergism was observed between Medihoney®  
and rifampicin against MRSA and S. aureus 
Muller et al., 2013 
Omani honey and 
gentamicin 
Agar well diffusion S. aureus The rate of eliminating micro-organisms was 
greater when honey was combined with 
gentamicin, enhancing gentamicin activity by 
22%.  
Al-Jabri et al., 2005 
Honey of Indian origin and 
gentamicin, amikacin and 
ceftazidime 
Broth dilution  Pseudomonas 
spp., Klebsiella 
spp. 
Combinations of honey and gentamicin, 
amikacin and ceftazidime individually 
demonstrated synergy against Pseudomonas 
spp. 
Karayil et al., 1998 
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COMBINATION METHOD PATHOGEN RESULTS REFERENCE 
Manuka honey and 
amoxicillin, penicillin G, 
cephalexin, ceftizoxime, 
colistin, erythromycin, 
gentamicin, imipenem, 
kanamycin, mupirocin, 
piperacillin/tazobactam, 
ciprofloxacin, rifampicin, 
tetracycline and 
vancomycin 
Disc diffusion, E 
test strips, serial 
broth dilution, 
chequer boards, 
growth curves 
P. aeruginosa 
and MRSA 
Synergistic activity between Manuka honey 
and each of tetracycline, imipenem and 
mupirocin were observed against MRSA and 
additivity between each of Rifampicin, 
tetracycline and colistin and Manuka honey 
against P. aeruginosa 
Jenkins and Cooper, 
2012 
Honey and imipenem, 
ciprofloxacin, 
amoxicillin/clavulanic acid, 
sublactam/ampicillin, 
ceftriaxone, amikacin, 
aztreonam, vancomycin, 
methicillin 
Disc diffusion P. aeruginosa, 
coagulase-
positive 
Staphylococci, 
Enterobacter 
spp., Klebsiella 
spp. 
The combination of honey and antibiotic 
demonstrated a significant increase in the 
mean inhibition zones that was greater for 
honey alone. Exceptions were noted for 
amikacin and aztreonam. 
Abd-El et al., 2007 
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1.9 Study aims and objectives  
 
The aim of this study was to investigate the antimicrobial activity of SA honeys against 
potential wound pathogens. In addition, combination studies with conventional antibiotics as 
well as the physicochemical properties of these honeys were also investigated. 
 
In order to achieve this aim, the following objectives were outlined: 
 
1. Analysis of the antimicrobial minimum inhibitory concentration (MIC) of 83 honey samples 
utilising the agar dilution method. 
2. Analysis of the physicochemical properties of the honeys including pH, water content and 
sugar content. Impurification/adulteration was also investigated. Physicochemical properties 
were also correlated with antimicrobial activity.   
3. Analysis of the combined effect of honey with conventional antimicrobial medicines 
utilising the fractional inhibitory concentration (FIC) index was carried out to determine if the 
honey and these agents are synergistic, indifferent or antagonistic when investigated in 
combination. 
 
1.10 Potential benefits of this study 
 
1. Identification  of South African honeys with potential antimicrobial activity. 
2. Emphasis on the synergistic or additional benefits of combining SA honey with 
conventional antimicrobial agents. 
3. Possible decrease in the incidence of antimicrobial resistance by combining conventional 
antimicrobial agents with honey displaying antimicrobial activity.  
4. The study may be utilised as a strong motivator for export or promotion of the SA honey 
as a therapeutic ‘medi-honey’. 
5. Creating a platform for expanding ‘honey-based’ wound care to other complementarty 
agents thereby alleviating the constant use of conventional antimicrobial. 
 
1.11 Overview of this research report 
 
Chapter one provides an introduction and background to this study and outlines the 
challenges faced with wound management and conventional antimicrobial therapy. 
Conventional topical wound therapy in terms of antimicrobial wound dressings and the use 
of honey as an antimicrobial agent for primary wound care is also reviewed. This chapter 
highlights the rationale, aim, objectives and potential benefits of this study. 
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Chapter two investigates the antimicrobial properties of SA honeys with respect to 
pathogens associated with wound infections utilising the minimum inhibitory agar dilution 
assay. 
 
Chapter three investigates the antimicrobial effect of honey in combination with 
conventional antibiotics and antifungal agents to assess if antimicrobial effects are additive, 
synergistic, indifferent or antagonistic. 
 
Chapter four assesses the physicochemical properties of the honey samples as pH, water 
content and sugar content are known to impact antimicrobial activity. 
  
Chapter five provides the conclusion of this research report and discusses limitations, 
recommendations and future investigations. 
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CHAPTER 2 
INVESTIGATION INTO THE ANTIMICROBIAL ACTIVITY OF VARIOUS SOUTH AFRICAN 
HONEYS 
 
2.1 Introduction 
World-wide research has been performed on honey however there is currently very little data 
existing with regards to SA honey. In order to scientifically validate the traditional therapeutic 
use of honey as a wound dressing, the antimicrobial activity of various SA honeys was 
investigated. Extensive antimicrobial testing against a variety of common wound pathogens 
was conducted to determine the minimum concentration of honey that can successfully 
inhibit the growth of these pathogens tested in this study.   
Evaluation of the potential antimicrobial properties of the various SA honeys revolved around 
rigorous in vitro testing.  
2.2 Materials and methods 
2.2.1 Acquisition of honey samples 
In collaboration with Kim Morgado (beekeeper in Johannesburg) and Mike Allsopp from the 
Honey Research Station, Agricultural Research Council in Stellenbosch, a variety of un-
heated, non-irradiated, un-clarified as well as un-processed honey samples from various 
botanical sources throughout SA (Eastern Cape, Western Cape, Kwa-Zulu Natal, 
Mpumalanga, North West, Limpopo, Free State) were collected. All honeys varied in colour, 
viscosity, taste and smell (Figure 2.1). 
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Figure 2.1: Some of the varieties of honeys acquired from various botanical sources across 
SA. 
Samples were collected from December 2005 to September 2011 in order to accommodate 
different floral types and seasonal variation. Samples were sourced throughout South Africa 
as geographical location may influence the antimicrobial efficacy (Irish et al, 2011). A map 
indicating the geographical location of the honey samples is illustrated in Figure 2.2 which 
further illustrated that the majority of samples collected were from the Western Cape region. 
This is due in part to the vast floral biodiversity exhibited in the Cape region (Goldblatt and 
Manning, 2002) and the supplier residing in this region.  
2.2.2 Processing, referencing and coding of honey samples 
Honey samples were stored away from light and at room temperature. Honey types were 
identified and the perceived source (where possible) noted by the apiarists. The samples 
were numbered, and coded in order to reference and trace the respective samples (Table 
2.1). In addition, the samples were recorded according to their scientific and common 
names, date of collection, and geographical location as per Table 2.1. The samples were 
numbered and coded in order to reference and trace the respective samples. Honey 
samples were labelled whereby a number according to order of receipt was issued followed 
by the perceived source (where possible) noted by the apiarists and thereafter a 
geographical code given based on the province where the samples were attained. The focus 
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of the current study was the antimicrobial analysis of 55 samples collected in the year of 
analysis (2011 (Table 2.2). Concentrations of honey were expressed as the percentage of 
honey volume per total volume (v/v). A subset of older honey samples (collected from 2005) 
from the same geographical region with perceived equivalent botanical source was then 
selected to analyse possible antimicrobial efficacy variations with ageing of honey as a key 
independent variable assessed. Seven samples from 2010 were analysed, three from 2009, 
sixteen from 2008, one from 2007 and one sample with details unknown was also evaluated 
as these details could not be provided by the supplier of the honey.   
 
 
Figure 2.2: Map of SA illustrating geographical region and number of honey samples 
acquired from each region. 
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Table 2.1: South African honey samples collected in various geographical regions in 2011. 
 
REFERENCE CODE SCIENTIFIC NAME ( PERCEIVED BOTANICAL SOURCE) LOCALITY PROVINCE 
SOURCE 
DATE 
1–(CITYMIXA/EC) Eucalyptus spp., Trichilia emetica, Erythina spp. (Inner city 
A mix) 
East London E. Cape Apr-11 
2-(CITYMIXB/EC) Callistemon viminalis, Eugenia spp., Eucalyptus spp., 
Jacaranda spp., Ocimum basilicum, Thymus spp.,  
Lavandula spp.,  Leguminosae spp., Juglans cinerea,  
Pisum sativum, vitis spp., Persea spp. and others, (Inner 
city B mix) 
East London E. Cape Apr-11 
3-(CITYMIXC/EC) Acacia karroo, Allophylus decipiens, Allophylus natalensis, 
Apodytes dimidiata, Asparagus spp., Buddleja auriculata, 
Buddleja saligna, Carissa bispinosa, Dombeya rotundifolia, 
Dovyalis caffra, Dovyalis longispina, Dovyalis zeyheri, 
Ehertia rigida, Euclea natalensis, Grewia occidentalis, 
Gymnosporia mossambicensis, Pavetta revoluta, Plumbago 
auriculata, Ptaeroxylon obliquum, Putterlickia pyracantha, 
Putterlickia verrucosa, Rhus glauca, Rhus incisa, Rhus 
laevigata, Syzygium cordatum, Tecomaria capensis 
Strand W. Cape Apr-11 
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REFERENCE CODE SCIENTIFIC NAME ( PERCEIVED BOTANICAL SOURCE) LOCALITY PROVINCE 
SOURCE 
DATE 
 
4-(CITYMIX/EC) Unknown Strand W. Cape Apr-11 
 
5-(CITYMIXTUART/WC) 
Eucalyptus gomphocephala and Unknown (Tuart gum and 
City Mix) Strand W. Cape Apr-11 
 
6-(MANGO/WC) Mangifera indica (Mango) Dutoitskloof W. Cape Apr-11 
 
7–(FYNBOS/WC) Ericas spp. (Fynbos) Bainskloof W. Cape Apr-11 
8–(ECFYNBOS/WC) Eucalyptus cladocalyx and Erica spp. (Sugar Gum and 
Fynbos) Llandudno W. Cape Jan-11 
 
9–(STANDVELD/WC) (Strandveld) Hermanus W. Cape Feb-11 
 
10-(BUCHU/WC) Agathosma spp. Hopefield W. Cape Feb-11 
 
11-(STANDVELD/WC) Unknown Heidelburg W. Cape Jan-11 
 
12–(BUSHVELD/KZN) (Coastal Sandy Bushveld) Maputaland KZN Jan-11 
 
13–(BUFFALOTHORN/NC) Ziziphus mucronata (Buffalo Thorn) Northern Cape N. Cape Mar-11 
 
14–(HOOKTHORN/NC) Acacia mellifera (Hookthorn) Northern Cape N. Cape Mar-11 
15–(ONION/WC) Allium cepa (Onion) Oudtshoorn W. Cape Feb-11 
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REFERENCE CODE SCIENTIFIC NAME ( PERCEIVED BOTANICAL SOURCE) LOCALITY PROVINCE 
SOURCE 
DATE 
16-(FYNBOS/WC) Erica spp. (Fynbos) Mossel Bay W. Cape Feb-11 
17-(AKMS/FS) Acacia karroo and medicago sativa (Soetdoring and 
Lucerne) Glen Free State Feb-11 
18–(MIXEDGUM/FS) (Mixed gums) Bainsvlei Free State Mar-11 
19–(CITYMIX/FS) (City mix) Rayton Free State Mar-11 
20–(FORRESTREDGUM/WC) 
Eucalyptus tereticornis (Forrest red gum) 
Mariendahl 
Stellenbosch W. Cape Jan-11 
21–(SUGARGUM/WC) Eucalyptus cladocalyx (Sugar Gum) Kromme Rhee W. Cape Mar-11 
22-(FYNBOS/WC) 
Erica spp. 
Lourensford 
Somerset west W. Cape Mar-11 
24–(STRANDVELD/WC) (Strandveld wild flowers) Still Bay W. Cape Apr-11 
25–(BUCFYN/WC) Agathosma spp./ Erica spp. (Fynbos\Buchu) Hermanus W. Cape Mar-11 
26–(FYNBOS/WC) Erica ericoides (Fynbos) Cape Point W. Cape Mar-11 
27–(AEF/WC) Agathosma spp./Eucalyptus ficifolia (Buchu and Red 
Flowering Gum) Kogelburg W. Cape Jan-11 
31–(MACADAMIA/WC) Macadamia integrifolia (Macadamia) Herbertsdal W. Cape Jan-11 
32-(FYNBOS/WC) Erica spp. Herbertsdal W. Cape Jan-11 
33-(CITRUS/WC) Citrus spp. Citrusdal W. Cape Mar-11 
34-(ONION/FYNBOS) Allium Cepa/Erica spp. Ceres W. Cape Mar-11 
35-(FYNBOSEC/WC) Eucalyptus conferruminata/Erica spp. (Spider Gum and 
Fynbos) Pearly Beach W. Cape Mar-11 
36-(EUCLADFIC/WC) Eucalyptus cladocalyx/Eucalyptus ficifolia Somerset West W. Cape Mar-11 
37–(FYNBOS/WC) Erica spp. (Fynbos) Stanford W. Cape Mar-11 
38–(WASBESSFYNBOS/WC) Morella cordifolia/Erica spp. (Wasbessie and fynbos) Albertina W. Cape Mar-11 
39-(SUGUARGUM/WC) Eucalyptus cladocalyx Moorreesburg W. Cape Feb-11 
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REFERENCE CODE SCIENTIFIC NAME ( PERCEIVED BOTANICAL SOURCE) LOCALITY PROVINCE 
SOURCE 
DATE 
40–(FYNBOSGUARRI/WC) Erica spp. and Euclea racemosa (Fynbos, guarri) Stanford W. Cape Jan-11 
41–(INDIGENOUS/WC) Podocarpus latifolius, Dalbergia melanoxylon, Acacia 
spp.,Pyrus spp., Eucalyptus tereticornis, Acacia karroo, 
Melaleuca spp., Acacia erioloba, Aloe spp., pelargonium 
spp., Cotyledon orbiculata, Aponogeton distachyos, 
Nymphaea spp., Hypoxis hemerocallidea (indigenous and 
others) Oudtshoorn W. Cape Feb-11 
43–(KAROOVELD/EC) (Karoo veld) Aberdeen E. Cape Mar-11 
44–(STRANDVELD/WC) (Strandveld) 
 Albertina W. Cape Mar-11 
45–(FYNBOS/WC) Erica spp.  (Fynbos) Still Bay W. Cape Mar-11 
46-(KARRIGUM/WC) Eucalyptus diversicolor Knysna W. Cape Mar-11 
47–(SALIGNAGUM/KZN) Eucalyptus grandis (Saligna Gum) Howick KZN Mar-11 
48–(BRE/EC) (Bushveld, riverine forest, euphorbias) Baviaanskloof E. Cape Feb-11 
49-(CITRUS/EC) 
Citrus spp. (Citrus) 
Sundays River 
Valley E. Cape Feb-11 
50-(HOOKTHORN/WC) Acacia mellifera Prieska W. Cape Mar-11 
51-(URBANFORAGE/WC) (Urban Forage) Liesbeeck River W. Cape Mar-11 
52-(SUBURBANGARDEN/WC) (Suburban gardens) Constantia W. Cape Mar-11 
53-(LITCHI/MP) Litchi chinensis (Litchi) White River Mpumalanga Jan-11 
154-(ONION/WC) Allium cepa Mossel Bay W. Cape Jan-11 
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Reference code: Sample number – (Common name or scientific name/ Province abbreviated); WC – Western Cape; NC- Northern Cape; EC- 
Eastern Cape; KZN- Kwa-Zulu Natal; FS- Free State; MP- Mpumalanga; LIM – Limpopo; NZ – New Zealand 
 
 
REFERENCE CODE SCIENTIFIC NAME ( PERCEIVED BOTANICAL SOURCE) LOCALITY PROVINCE 
SOURCE 
DATE 
156-(BUFFALOTHORN/NC) Ziziphus mucronata (Buffalo Thorn) Douglas N. Cape Jan-11 
158-(BUFFALOTHORN/NW) Ziziphus mucronata (Buffalo Thorn) Christiana North West Jan-11 
159-(BUFFALOTHORN/NW) Ziziphus mucronata (Buffalo Thorn) Potchefstroom North West Jan-11 
160-(BOEKENHOUT/LIM) Faurea saligna (Boekenhout) Naboomspruit Limpopo Jan-11 
162-(SALIGNAGUM/KZN) Eucalyptus grandis (Saligna Gum) Harding KZN Sep-11 
167-(SUNFLOWER/NW) (Sunflower) Ventersdorp North West Feb-11 
54-(MANUKA/NZ) Leptospermum scoparium (Manuka honey) Control Coromandel New Zealand Feb-11 
55-(MANUKA/NZ) Leptospermum scoparium (Manuka honey) Control Kailaia New Zealand Feb-11 
56-(MANUKA/NZ) Leptospermum scoparium (Manuka honey) Control Ohakune New Zealand Feb-11 
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REFERENCE CODE 
SCIENTIFIC NAME ( PERCEIVED 
BOTANICAL SOURCE) LOCALITY PROVINCE SOURCE DATE 
60-(YELLOWBOX/WC) Eucalyptus melliodora (Yellow Box) Darling W. Cape Jul-08 
61-(STRANDVELD/WC) Unknown (Strandveld) Hopefield W. Cape Jul-08 
62-(SUGARGUM/WC) Eucalyptus cladocalyx (Sugar Gum) Paarl W. Cape Jul-08 
64-(CITRUS/WC) Citrus spp. (Citrus) Citrusdal W. Cape Jul-08 
69-(OLIVEFYN/SC) 
Olea spp. and Erica spp. (Wild olive and 
Fynbos) Southern Cape S. Cape Jan-09 
80-(FORESTREDGUM/WC) Eucalyptus tereticornis (Forest Red Gum) Elsenburg W. Cape Sep-08 
86-(LITCHI/MP) Litchi chinensis (Litchi) White River Mpumalanga Jul-08 
90-(FYNBOS/WC) Erica spp. (Fynbos) Bainskloof W. Cape Jul-08 
94-(HOOKTHORN/NC) Acacia mellifera (Hookthorn) Douglas N. Cape Jul-08 
106-(ONION/WC) Allium cepa (Onion) Ceres W. Cape Apr-08 
109-(FYNBOS/WC) Erica spp. (Fynbos) Mossel Bay W. Cape Jul-08 
116-(FYNBOS/SC) Erica spp. (Fynbos) S Cape S. Cape Jul-08 
117-(WILDFLOWERS/GP) (Wild flowers) Highveld Gauteng Jul-08 
119-(BUFFALOTHORN/NW) Ziziphus mucronata (Buffalo Thorn) Christiana North West Jul-08 
123-(SALIGNAGUM/KZN) Eucalyptus grandis (Saligna Gum) Harding KZN Mar-08 
135-(FYNBOS/WC) Erica spp. (Fynbos) Stanford W. Cape Jul-07 
139-(BLUEBUSH/NW) Diospyros lycioides (Blue Bush) Christiana North West Oct-10 
142-BUFFALOTHORN/NW) Ziziphus mucronata (Buffalo Thorn) Christiana North West 2010 
144-(FYNBOS/WC) Erica spp. (Fynbos) Mossel Bay W. Cape Oct/Nov/2010 
Table 2.2: Honey samples collected prior to 2011. 
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Reference code: Sample number – (Common name or scientific name/ Province abbreviated); WC – Western Cape; NC- Northern Cape; EC- 
Eastern Cape; KZN- Kwa-Zulu Natal; FS- Free State; MP- Mpumalanga; LIM – Limpopo; NZ – New Zealand 
REFERENCE CODE 
SCIENTIFIC NAME (PERCEIVED 
BOTANICAL SOURCE) LOCALITY PROVINCE SOURCE DATE 
145-(COSMOS/NP) Cosmos bipinnatus NP NP 2010 
146-(REDSYRING/LIM) Burkea africana (Red syringe) Waterberg Limpopo Jan-09 
148-(ALOE/NP) Greatheadii var davyana (Aloe) NP NP Aug-09 
149-(HOOKTHORN/NP) Acacia mellifera (Hookthorn) NP NP Oct-10 
150-(COMBRETUM/GP) Combretum and others (Wild Flora) North Pretoria Gauteng Oct/Nov 2010 
155-(CATTHORN/EC) Scutia myrinta (Cat Thorn) Port Alfred E. Cape Dec-2010 
96-(MANUKA/NZ) 
Leptospermum scoparium (Manuka honey) 
Control Unknown New Zealand Apr-2008 
97-(MANUKA/NZ) 
Leptospermum scoparium (Manuka honey) 
Control Unknown New Zealand Jul-2008 
147-(MANUKA/NZ) 
Leptospermum scoparium (Manuka honey) 
Control Unknown New Zealand Unknown 
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2.2.3 Test pathogen strains 
 
A variety of pathogens most commonly responsible for wound microbial colonisation and 
proliferation were selected to test the antimicrobial efficacy of the acquired honey samples. 
 
The pathogens included;  
• Six Gram-positive strains: Staphylococcus aureus (laboratory - ATCC 25923), S. 
aureus, (clinical – ATCC 6438300), MRSA (laboratory – ATCC 43300), MRSA 
(clinical – ATCC 43300), methicillin and gentamicin resistant S. aureus (laboratory – 
ATCC 33592), Staphylococcus epidermidis (laboratory – ATCC 2223). 
• One Gram-negative strain: Pseudomonas aeruginosa (laboratory – ATCC 9027). 
• Two yeast strains: Candida albicans (laboratory – ATCC 10231), Candida albicans 
(clinical – CA9B). 
 
Stock cultures for ATCC strains were obtained from Davies Diagnostics and clinical strains 
were obtained from Dr. M. Patel (Department of Oral Microbiology, University of the 
Witwatersrand). All pathogens were grown in Tryptone Soya Broth (TSB). The stock cultures 
were refrigerated at a temperature of -20 °C. A waiver was obtained for the use of clinical 
strains (Appendix B). 
 
2.2.4 Preparation of media: 
 
Tryptone Soya Agar (TSA) was prepared by suspending 30 g of Tryptone Soya powder in 
750 mL of distilled water. Tryptone Soya Broth (TSB) was prepared by suspending 40 g of 
Tryptone Soya powder in 1 L of distilled water. The agar and broth was subsequently 
autoclaved at 121 °C for 15 minutes. Sterility of the agar and broth were ensured by 
incubating the broth and agar to 37 °C for 24 hours before use and inspecting visually for 
contamination.  
 
2.2.5 Evaluation of the mean inhibitory concentration  
 
As per National Committee for Clinical Laboratory Standards (NCCLS) guidelines (2003), 
three to five isolated colonies were selected from a TSA agar plate culture. The growth was 
then transferred to a test tube containing 5 mL of TSB. The broth containing the culture was 
then incubated at 37 °C for 24 hours for bacterial pathogens and 48 hours for yeasts.  Purity 
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of cultures was ensured by streaking onto an agar plate and incubating at 37 °C for 24 hours 
for bacterial species and 48 hours for yeasts.  
 
The turbidity of the broth culture was visually adjusted with TSB to achieve a 0.5 McFarland 
Standard. The 0.5 McFarland standard suspension was then diluted to a 1:100 in sterile TSB 
which resulted in a concentration of approximately 1x107 colony forming units (CFU)/mL. 
Figure 2.3 describes the inoculation of honey-agar plates with the respective pathogens. A 
multipoint inoculator, multipointelite™ was utilised to automatically deliver the test pathogens 
to the honey-agar plate. The multipoint inoculator delivers approximately 1 – 2 µL on the 
agar surface. 
 
Antimicrobial activity was established by determining the MIC utilising the agar dilution 
method. Agar dilution involves the incorporation of different concentrations of the 
antimicrobial agent (honey) into a nutrient agar medium and the subsequent inoculation. The 
agar was contained in a water bath at 55 °C to ensure that it did not solidify and that its 
contained viscosity was desirable. The MIC was defined as the lowest concentration of 
honey required for inhibiting visible growth of the pathogens being investigated. Honey 
dilutions (v/v) of 50.00%, 25.00%, 12.50%, 6.25% and 3.13% were analysed. Honey dilutions 
were added to molten TSA medium that was allowed to equilibrate in a water bath at 55 °C.  
 
The agar and honey at various concentrations (50.00%, 25.00%, 12.50%, 6.25% and 3.13%) 
(v/v) were pipetted into sterile test tubes and subsequently vortex mixed to ensure a 
homogenous distribution of the mixture. The agar and honey solution was then poured into 
petri dishes to achieve a depth of 3 mm (20 mL per plate). This process should occur swiftly 
to prevent cooling, solidification before settling and the formation of bubbles. Cultures were 
inoculated onto the surface of the agar utilising a multipointelite innoculator as described in 
Figures 2.3. One millilitre of the 1:100 cultures was pipetted into three wells of the 
multipointelite innoculator.  After inoculation, the plates were allowed to stand for 30 minutes 
to ensure that the inoculum spots were absorbed into the agar. After inoculation, the agar-
honey dishes were incubated for 24 hours at 37 °C for Gram-positive and Gram-negative 
bacteria, subsequently removed with the results being read and then replaced back into the 
incubator. The plates were further incubated for an additional 24 hours to accommodate and 
investigate growth of the yeast species. Growth control plates of TSA were inoculated first 
and last to ensure the appropriate growth of test micro-organisms. To ensure accuracy and 
consistency, all MIC’s were performed in triplicate (N=3). Results were reported in 
accordance with the presence or absence of microbial growth on the agar plates. All MIC 
values were expressed in % (v/v). 
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WIRE LOOP STROKE SINGLE COLONY 
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TRANSFERRED TO 
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Figure 2.3: Flow Diagram illustrating the steps for inoculation of honey-agar plates and the multipointelite inoculator inoculating honey-agar 
plates. 
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2.2.6 Controls 
 
2.2.6.1 Artificial honey 
 
An artificial honey solution (39.00% w/v d-fructose, 31.00% w/v d-glucose, 8.00% w/v maltose, 
3.00 % w/v  sucrose and 19.00% w/v water) with a sugar content similar to honey was included 
in the assays as a control to determine antimicrobial effects due to sugar. Sugar is known to 
possess some antimicrobial properties (Molan, 2001; Basson and Grobler 2008). The 
artificial honey solution was autoclaved at 121 °C for 15 minutes and subjected to the agar 
dilution method at concentrations of 50.00%, 25.00%, 12.50%, 6.25% and 3.13% to mimic 
honey concentrations. 
 
2.2.6.2 Manuka honey 
 
This honey was utilised as a comparative control with which to compare SA honeys. Manuka 
honey is derived from the Leptospermum scoparium floral source, in New Zealand. Six 
samples were obtained where three of which were collected in 2011, two were collected in 
2008 and one of which the collection date is unknown.  
2.2.6.3 Phenol 
 
A 20% (w/v) phenol solution prepared by dissolving 20 g of phenol powder in 100 mL of 
sterile water, was utilised as a positive control. Phenol and agar were mixed to produce a 
20% phenol control and subsequently inoculated as honey agar plates. A blank TSA plate 
was utilised as a growth control. This was used between every honey-agar plate.  
 
2.2.6.4 Ciprofloxacin 
The broad-spectrum conventional antibiotic, ciprofloxacin, was also used as a control in this 
study. 
2.3 Results and discussion 
2.3.1 Mean inhibitory concentration 
The mean MIC sensitivity (% inhibition) of each honey collected in various geographical 
regions for the year 2011 is depicted in Table 2.3.  
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Table 2.3: Minimum inhibitory concentration (% inhibition) of samples collected in 2011. 
REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
1-(CITYMIXA/EC) 12.50 12.50 12.50 12.50 12.50 12.50 6.25 50.00 25.00 17.36±13.18 
2-(CITYMIXB/EC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
3-(CITYMIXB/EC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
4-(CITYMIX/WC) 6.25 6.25 6.25 6.25 12.50 6.25 6.25 50.00 25.00 13.89±14.91 
5-(CITYMIXTUART/WC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 ±0.00 
6-(MANGO/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
7-(FYNBOS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
8-(ECFYNBOS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
9-(STRANDVELD/WC) 25.00 25.00 25.00 25.00 25.00 25.00 6.25 50.00 50.00 28.47±13.66 
10-(BUCHU/WC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
11-(STRANDVELD/WC) 50.00 50.00 50.00 50.00 50.00 25.00 25.00 50.00 50.00 44.44±11.02 
12-(BUSHVELD/KZN) 12.50 12.50 12.50 12.50 12.50 12.50 6.25 25.00 25.00 14.58±6.25 
13-
(BUFFALOTHORN/NC) 
25.00 25.00 25.00 25.00 25.00 25.00 6.25 25.00 50.00 25.69±11.02 
14-(HOOKTHORN/NC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
15-(ONION/WC) 12.50 12.50 12.50 12.50 12.50 12.50 12.50 25.00 25.00 15.28±5.51 
16-(FYNBOS/WC) 6.25 6.25 6.25 6.25 6.25 6.25 6.25 25.00 25.00 10.42±8.27 
17-(AKMS/FS) 12.50 12.50 12.50 12.50 12.50 12.50 6.25 25.00 25.00 
 
14.58±6.25 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
18-(MIXEDGUM/FS) 6.25 6.25 6.25 6.25 6.25 6.25 6.25 50.00 50.00 15.97±19.29 
19-(CITYMIX/FS) 6.25 6.25 6.25 6.25 6.25 6.25 6.25 50.00 6.25 11.11±14.58 
20-
(FORRESTREDGUM/W
C) 
6.25 12.5 12.5 6.25 6.25 6.25 6.25 50.00 50.00 17.36±18.69 
21-(SUGARGUM/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
22—(FYNBOS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
24-(STRANDVELD/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 25.00 ±0.00 
25–(BUCFYN/WC) 25.00 25.00 25.00 25.00 25.00 12.50 12.50 50.00 25.00 25.00±10.83 
26-(FYNBOS/WC) 12.50 12.50 12.50 12.50 12.50 12.50 6.25 50.00 50.00 20.14±17.05 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
27-(AEF/WC) 25.00 25.00 25.00 25.00 25.00 12.50 6.25 25.00 12.50 20.14±7.51 
31-(MACADAMIA/WC) 25.00 25.00 25.00 25.00 25.00 12.50 12.50 50.00 50.00 27.78±13.66 
32-(FYNBOS/WC) 50.00 50.00 50.00 12.50 50.00 25.00 25.00 50.00 50.00 40.28±15.02 
33-(CITRUS/WC) 50.00 50.00 25.00 25.00 50.00 25.00 25.00 50.00 50.00 38.89±13.18 
34-(ONION/FYNBOS) 50.00 50.00 50.00 50.00 50.00 50.00 25.00 50.00 50.00 
 
47.22±8.33 
35-(FYNBOSEC/WC) 25.00 25.00 25.00 25.00 25.00 25.00 12.50 50.00 25.00 
 
26.39±9.77 
36-(EUCLADFICI/WC) 12.50 12.50 12.50 12.50 25.00 12.50 6.25 25.00 25.00 
 
15.97±7.06 
37-(FYNBOS/WC) 12.50 25.00 12.50 12.50 25.00 25.00 25.00 50.00 50.00 26.39±14.58 
38-
(WASBESSFYNBOS/C) 
12.50 12.50 12.50 12.50 12.50 12.50 6.25 50.00 50.00 20.14±17.05 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
39-(SUGARGUM/WC) 50.00 50.00 50.00 50.00 50.00 25.00 50.00 50.00 50.00 47.22±8.33 
40-
(FYNBOSGUARRI/WC) 
25.00 25.00 25.00 25.00 50.00 25.00 12.50 50.00 50.00 31.94±14.13 
41-(INDIGENOUS/WC) 12.50 12.50 6.25 6.25 12.50 12.50 6.25 25.00 25.00 13.19±7.29 
43-(KAROOVELD/EC) 12.50 12.50 12.50 25.00 12.50 12.50 6.25 50.00 50.00 21.53 ±16.86 
44-(STRANDVELD/WC) 12.50 25.00 12.50 12.50 25.00 12.50 6.25 50.00 50.00 22.92±16.54 
45-(FYNBOS/WC) 12.50 12.50 12.50 12.50 12.50 12.50 6.25 50.00 50.00 20.14±17.05 
46-(KARRIGUM/WC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
47-
(SALIGNAGUM/KZN) 
50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
48-(BRE/EC) 25.00 25.00 25.00 25.00 25.00 25.00 12.50 50.00 50.00 29.17±12.50 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
49-(CITRUS/EC) 50.00 50.00 50.00 50.00 50.00 50.00 6.25 50.00 50.00 45.14±14.58 
50-(HOOKTHORN/WC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
51-
(URBANFORAGE/WC) 
12.50 6.25 6.25 6.25 12.50 6.25 6.25 50.00 50.00 17.36±18.69 
52-
(SUBURBANGARDEN/
WC) 
6.25 12.50 6.25 6.25 12.50 6.25 6.25 50.00 25.00 14.58±14.66 
53-(LITCHI/MP) 50.00 50.00 50.00 50.00 50.00 50.00 6.25 50.00 50.00 45.14±14.58 
154-(ONION/WC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
156-
(BUFFALOTHORN/NC) 
25.00 25.00 25.00 25.00 25.00 25.00 12.50 50.00 50.00 29.17±12.5 
158-
(BUFFALOTHORN/NW) 
25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±11.02 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
159-
(BUFFALOTHORN/NW) 
25.00 25.00 25.00 25.00 25.00 25.00 12.50 50.00 50.00 29.17±12.50 
160-
(BOEKENHOUT/LIM) 
25.00 25.00 25.00 25.00 25.00 6.25 6.25 50.00 50.00 26.39±15.55 
162-
(SALIGNAGUM/KZN) 
25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 30.56±12.50 
167-
(SUNFLOWER/NW) 
25.00 25.00 25.00 25.00 25.00 25.00 12.50 50.00 50.00 
29.17D±10.1
8 
Mean of pathogens 
26.36 
±15.39 
26.93 
±15.02 
25.80 
±15.17 
25.23±14.92 
27.73±15.
06 
23.63 
±14.37 
18.75 
±15.12 
45.91 
±9.33 
43.07 
±12.31 
 
(M&G)* = methicillin and gentamicin resistant S. aureus (laboratory – ATCC 33592) 
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Table 2.4: Minimum inhibitory concentration (% inhibition) of controls. 
CONTROL 
S. aureus 
ATCC 25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC 2223 
P. aeruginosa 
ATCC 9027 
C. albicans 
ATCC 10231 
C. albicans 
clinical MEAN MIC 
54-(MANUKA/NZ) 12.50 12.50 12.50 12.50 12.50 25.00 12.50 25.00 12.50 15.28±5.51 
55-(MANUKA/NZ) 6.25 12.50 6.25 6.25 25.00 12.50 12.50 50.00 50.00 20.17±17.89 
56-(MANUKA/NZ) 50.00 50.00 50.00 25.00 50.00 25.00 25.00 50.00 50.00 41.67±12.50 
Artificial Honey 50.00 50.00 50.00 50.00 50.00 25.00 25.00 50.00 50.00 44.44±11.02 
Ciprofloxacin 
(µg/ml) 0.078 0.078 0.078 1.25 0.078 0.30 0.25 N/A N/A N/A 
Amphotericin B N/A N/A N/A N/A N/A N/A N/A 1.25 1.25 N/A 
N/A Not applicable 
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The MIC against all pathogens ranged from 10.42-50.00%, with sample 16-(FYNBOS/WC) 
displaying the most broad-spectrum activity. At a concentration of 50.00%, the growth 
against all nine test pathogens was completely inhibited by all honey samples. This was 
consistent with artificial honey thus it can be postulated that the antimicrobial activity of these 
samples can be attributed to hyper-osmolar effects as the carbohydrate concentration has a 
pivotal effect in the antimicrobial activity of honeys above 25%. Hyper-osmolarity prevents 
the growth of bacteria and promotes wound healing (Basson and Grobler, 2008). It was 
observed that P. aeruginosa was the most sensitive strain, as the mean MIC for all honeys 
tested against P. aeruginosa was 18.75±15.12%.  The mean MIC sensitivity of each honey 
collected in 2011 to the respective pathogen strains are reported in Figure 2.4.  
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Figure 2.4: Mean MIC results for all pathogens tested against SA honey samples. 
Manuka honey and artificial honey were utilised as controls (Table 2.4). The antimicrobial 
activity of these samples ranged from 15.28±5.51-41.67±12.50% (N=3), with the average 
activity of these three samples being 25.69±14.04%. Any sample with an MIC ≤ 25.69% was 
considered desirable and good. Currently in Australia and New Zealand, Medihoney® and 
Manuka honey are marketed as therapeutic honeys suitable for use in ulcers, infected 
wounds and burns. Research has indicated that both these honeys, derived from the 
Leptospermum spp., have considerable antimicrobial activity against various wound 
organisms as well as antibiotic resistant bacteria (Brady et al., 2004). The Manuka honey 
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from Coromandel, New Zealand, (54-MANUKA/NZ) exhibited the most desirable 
antimicrobial activity of the three samples tested. Samples tested including; {1-
(CITYMIXA/EC), 4-(CITYMIX/WC), 12–(BUSHVELD/KZN),  15-(ONION/WC), 16–
(FYNBOS/WC), 17–(AKMS/FS), 18–(MIXEDGUM/FS),  19–(CITYMIX/FS), 20–
(FORRESTREDGUM/WC), 24–(STRANDVELD/WC), 25–(BUCFYN/WC), 26–
(FYNBOS/WC), 27–(AEF/WC), 36–(EUCLADFICI/WC), 38–(WASBESSFYNBOS/WC), 41–
(INDIGENOUS/WC), 43–(KAROOVELD/EC), 44–(STRANDVELD/WC), 45–(FYNBOS/WC), 
51–(URBANFORAGE/WC) and 52-(SUBURBANGARDEN/WC)} had a greater antimicrobial 
activity (lower % inhibition) than  when compared to the mean Manuka honey samples. 
Honey sample (13–(BUFFALOTHORN/NC) displayed antimicrobial activity equivalent to that 
of the mean Manuka honey activity. Honey sample 16–(FYNBOS/WC) displayed the 
greatest antimicrobial activity with a mean MIC of 10.42±8.27%. The Manuka honey sample 
54-(MANUKA/NZ) with the best antimicrobial activity observed for the controls had a mean 
MIC of 15.28%. Seven honey samples including; {4-(CITYMIXA/EC), 12-(BUSHVELD)/KZN, 
16-(FYNBOS/WC), 17-(AKMS/FS), 19-(CITYMIX/FS), 41-(INDIGENOUS/WC) and 52-
SUBURBANGARDEN/WC} had comparatively superior activity, having MICs lower than 
15.28% observed for the Manuka honey sample exhibiting the best antimicrobial activity. 
 
Honey samples 1-(CITYMIXA/EC), 4-(CITYMIX/WC), 9-(STRANDVELD/WC), 12-
(BUSHVELD/KZN), 13-(BUFFALOTHORN/KZN), 16-(FYNBOS/WC), 17 –(AKMS/FS), 18-
(MIXEDGUM/FS), 19-(CITYMIX/FS), 20-(FORRESTREDGUM/WC), 26-(FYNBOS/WC), 27-
(AEF/WC), 36-(EUCLADFICI/WC), 38-(WASBESSFYN/WC), 41-(INDIGENOUS/WC), 43-
(KAROOVELD/EC), 44-(STRANDVELD/WC), 45-(FYNBOS/WC), 49-(CITRUS/EC), 51-
(URBANFORAGE/WC), 52-(SUBURBANGARDEN/WC), 53-(LITCHI/MP), and 160-
(BOEKENHOUT/LIM) demonstrated considerable efficacy (MIC = 6.25%) against P. 
aeruginosa. This holds promise for SA honey as an alternative antimicrobial because of the 
severity of Pseudomonas-related infections particularly in immunocompromised patients 
(Speert, 2002). This Gram-negative organism is considered to be one of the most serious 
clinical complications in burn patients resulting in systemic infection (Nasser et al., 2003). 
Pseudomonas spp. are also commonly associated with nosocomial infections (Khoo et al., 
2010). This pathogen is often difficult to eradicate as it develops antibiotic resistance 
(Lambert, 2002). Mullai and Menon (2005) assessed the antimicrobial activity of Manuka 
honey (Australia), Heather honey (United Kingdom) and Khadikraft honey (India), against 
152 P. aeruginosa strains, which exhibited an MIC ranging from 10.00% - 20.00% for all 
honeys tested. Mandal and co-workers (2010), reported an MIC value of 3.50% (v/v) for 
Pseudomonas isolates tested against a honey sample harvested from an indica hive in India. 
Cooper (1999) also reported that Manuka honey produced an MIC ranging from 5.50-8.70% 
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for P. aeruginosa strains from infected wounds (Cooper, 1999). Similarly, Cooper and co-
workers (2002) reported that Manuka honey had an MIC value of 7.50% against clinical 
strains of P. aeruginosa from infected burn wounds (Cooper et al., 2002). An in vivo 
investigation by Khoo and co-workers (2010), revealed that P. aeruginosa was inhibited by 
Tualang honey at a concentration of 0.1 mL/cm2. In this study, it was observed that 41.82% 
of samples tested had an MIC value of 6.25% against P. aeruginosa. SA honey thus 
demonstrates the potential to heal potentially problematic burn wounds in patients that may 
lead to systemic sepsis. This is because it has been anticipated that honeys which produce 
an MIC between 10.00% to 20.00% should be effective in eradicating Pseudomonas 
infections (Mullai and Menon, 2005).  
S. epidermidis has been commonly identified in skin wounds and is considered to be part of 
the natural skin flora. This commensal can be pathogenic and has also developed antibiotic 
resistance (Basualdo et al., 2007; Chusri et al., 2012). S. epidermidis infections are usually 
acquired nosocomially (Raad et al., 1998). This study confirmed that S. epidermidis was 
substantially inhibited with a mean MIC of 23.63±14.37% for all honeys tested. A fraction of 
samples tested (14.55%) resulted in an MIC of 6.25% whereas another fraction of samples 
tested (25.45%) resulted in an MIC of 12.50%. Manuka honey tested against S. epidermidis 
resulted in an MIC that ranged from 12.50-25.00%. Honey samples 4-(CITYMIX/WC), 16-
(FYNBOS/WC), 18-(MIXEDGUM/FS), 19-(CITYMIX/FS), 20-(FORRESTREDGUM/WC), 51-
(URBANFORAGE/WC), 52-(SUBURBANGARDEN/WC) and 160-(BOEKENHOUT/LIM) 
exhibited strong efficacy against S. epidermidis with all samples demonstrating an MIC value 
of 6.25%.  
 
The data in this study also demonstrates that SA honey has antimicrobial activity against S. 
aureus, a pathogen commonly present in skin wounds (Tan et al., 2009). S. aureus has 
developed antibiotic resistance and is a clinical concern globally. MRSA is usually involved 
in difficult to treat skin and complicated underlying tissue infections (David and Daum, 2010). 
A study by Sherlock and co-workers (2010) underlined the testing of honey on S. aureus and 
reported that Ulmo honey (Eucryphia cordifolia) from Chile had MIC values of 3.1-6.3% (v/v) 
compared to the Manuka honey sample which had an MIC of 12.50% (v/v). French and co-
workers (2005) reported that Manuka honey and pasture honey inhibited S. aureus at 2.70-
5.00% (v/v). In a clinical investigation carried out by Simon and co-workers (2009), a 12 year 
old patient with cancer had a wound infected with MRSA and the wound was treated with a 
local antiseptic for 12 days. Despite this, the infection did not subside. The patient could not 
commence chemotherapy till the infection was cleared. After treatment with Medihoney®, a 
leptospermum honey, the infection subsided within two days (Tan et al., 2009). In general, 
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results from the majority of the samples tested in this study revealed that the laboratory 
reference strain (ATCC 25923) had a lower MIC inhibitory value than the clinical strain. A 
lack of substantial differences could be noted between the five different Staphylococcus 
strains tested, as mean MICs ranged between 25.23-27.73%. These in vitro results indicate 
that some honeys could potentially be utilised clinically against S. aureus. Honey samples 4-
(CITYMIX/WC), 16–(FYNBOS/WC), 18–(MIXEDGUM/FS), 19–(CITYMIX/FS), 20–
(FORRESTREDGUM/WC) and 52-(SUBURBANGARDEN/WC) demonstrated the greatest 
efficacy against all four S. aureus strains tested with all samples having an MIC value of 
6.25% against all laboratory strains and clinical strains with the exception of 20–
(FORRESTREDGUM/WC) and 52-(SUBURBANGARDEN/WC) which had an MIC of 12.50% 
against the clinical strains and 4-(CITYMIX/WC) had an MIC of 12.50% against the against 
the methicillin and gentamicin resistant S. aureus. 
 
Candida spp. are considered to be one of the most significant opportunistic fungal 
pathogens and a common cause of skin disease (Vázquez et al., 2013). The majority of 
samples tested against C. albicans had an MIC value of 50.00%. The Manuka honey 
samples tested also had an MIC of 50.00% with the exception of one sample, 54-
(MANUKA/NZ), which inhibited the laboratory strain at 25.00% and its clinical counterpart at 
12.50%. Honey samples 19-(CITYMIX/FS) and 27-(AEF/WC) had an MIC of 6.25% and 
12.5% respectively for the clinical strain of C. albicans. The antimicrobial efficacy of SA 
honeys tested are thus more sensitive to bacterial species than fungal species and this 
corresponds with previous studies (Basson and Grobler, 2008). Brady and co-workers 
(2004) conducted a survey of non-Manuka honey which revealed that the growth of Candida 
spp. was enhanced by selected honeys (Brady et al., 2004). This was possibly due to the 
presence of sugar which facilitated the fungal growth. A related study demonstrated that 
certain Iranian honeys required a 36.30% concentration or greater to be inhibitory against C. 
albicans (Khosravi et al., 2008).  Hydrogen peroxide dependent honeys have been reported 
to be more effective against fungal organisms than non-peroxide honeys, such as Manuka 
honey (Irish et al., 2011).  
2.3.2 Geographical location 
Various studies on honey have shown that there are immense antimicrobial differences 
within different honeys and this is directly related to the different countries or regions from 
which they are sourced. The geographical location of the floral origin may affect the 
phytochemical composition and physiology of the floral species which essentially affects the 
honey which has been harvested from this flora. Diversity of the plant species is dependent 
on environmental factors such as sunlight, moisture and soil composition (Henriques et al., 
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2005; Kaskoniene and Venskutonis, 2010). It has been postulated that the difference 
between countries can be attributed to varying compositions of pollen or nectar which has 
the greatest effect on honey composition (Kaskoniene and Venskutonis, 2010).  
Karousou and co-workers (2005), demonstrated that essential oil composition in honey was 
dependent on geographical location even when compared within same plant species. Thus, 
the composition can be substantially different even for honeys of the same floral origin. This 
was further demonstrated by Irish and co-workers (2011), who reported a variation in 
hydrogen peroxide activity within the equivalent floral species confirming that environmental 
conditions in different regions play a role in the relationship between floral source and non-
peroxide activity (Irish et al., 2011). 
The honeys tested in this study were collected from various provinces in SA. Figure 2.5 
demonstrates the geographical regions in SA where the honey samples were collect and the 
relative percentage of honey samples of the total collected from the respective regions.  
 
Figure 2.5: Graphical representation of the geographical regions in SA where the honey 
samples were collected and the relative percentage of honey samples of the total collection 
from the respective regions.  
It was noted that the samples with  the most favourable antimicrobial activity originate from 
the Western Cape {4-(CITYMIX/EC), 16-(FYNBOS/WC), 12-(BUSHVELD/KZN), 17-
(AKMS/FS), 36-(EUCLADFICI/WC), 41-(INDIGENOUS/WC), 52-
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(SUBURBANGARDEN/WC)} and the Free State {18-(MIXEDGUM/FS) and 19-
(CITYMIX/FS)} in SA. This observation in turn may be due to the fact that the majority of the 
samples were collected from these regions.  
Honeys with considerable antimicrobial activity may be obtained from a number of different 
environments. An interesting finding was that samples of the perceived equivalent floral 
species from the same province differed in antimicrobial activity. Allium cepa samples from 
the Western Cape confirmed this, whereby the sample from Outdshoorn (Sample 15-
(ONION/WC) with a mean MIC of 15.28% displayed superior antimicrobial activity over 
sample 154-(ONION/WC), with a mean MIC of 50.00% obtained from Mossel Bay. Mossel 
Bay is at the coast and Oudtshoorn is 85 kilometres inland. The climate of the two cities 
differs, with higher temperatures reached in Oudtshoorn. The results thus demonstrate that 
geographical location plays a significant role in the honey’s antimicrobial activity.  
It has been further reported that honeys produced at one time in one location could vary in 
activity, suggesting that entomological factors play a substantial role (Irish et al., 2011). The 
health of individual bee colonies and the age of foraging workers could affect the foraging 
activity or the secretion of enzymes, thus affecting antimicrobial activity. Mandal and co-
workers (2010) stated that the type of honey produced by the foragers is dependent on the 
natural vegetative flowers blooming in different seasons and places. Forager’s preferences 
may result in the activity being affected due to it being produced from the nectar of 
numerous floral species. It is further documented by Ayaad and co-workers (2011) that the 
variation in the antimicrobial potency could be attributed to the source of the nectars which 
may have contributed to the difference in the antimicrobial honeys. Floral source determines 
many of the attributes of honey such as flavour, aroma, colour and composition.  
Citrus Sample 33-(CITRUS/WC) from the Western Cape displayed similar antimicrobial 
properties in comparison to the Sample 49-(CITRUS/EC) from the Eastern Cape with the 
exception of investigations against P. aeruginosa. Sample 49-(CITRUS/EC) produced an 
MIC of 6.25% against P. aeruginosa. Fynbos samples (7-(FYNBOS/WC), 16-
(FYNBOS/WC), 22-(FYNBOS/WC), 26-(FYNBOS/WC), 32-(FYNBOS/WC), 37-
(FYNBOS/WC) and 45-(FYNBOS/WC) originate from different areas in the Western Cape, 
however, antimicrobial efficacy variation occurs, thus demonstrating that geographical 
location is a noteworthy variable.  Sample 16-(FYNBOS/WC) with a mean MIC of 
10.42±8.27,  from Mossel Bay, demonstrated superior antimicrobial efficacy, followed by 
sample 45-(FYNBOS/WC) (mean MIC of 20.14±17.05) from Still Bay, 26-(FYNBOS/WC) 
(mean MIC of 20.14±17.05) from Cape Point, and 37-(FYNBOS/WC) (mean MIC of 26.39 
±14.5) from Stanford. However, other honey samples derived from the fynbos {Samples 7-
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(FYNBOS/WC), 22-(FYNBOS/WC) and 32-((FYNBOS/WC)} displayed no noteworthy 
antimicrobial properties in comparison. Mossel Bay and Still Bay are closer to the coast, 
compared to Bainskloof, Somerset West, Herbertsdal and Stanford. The positioning of these 
areas result in varying climates thus affecting the chemical constituents of the honeys. 
Eucalyptus cladocalyx samples 21-(SUGARGUM/WC) and 39-(SUGARGUM/WC) both 
originate from the Western Cape and both samples displayed similar antimicrobial efficacy. 
Eucalyptus grandis samples 47-(SALIGNAGUM/KZN) and 162-(SALIGNAGUM/KZN) both 
originate from Kwa-Zulu Natal displaying similar MIC values, however, no superior 
antimicrobial efficacy was noted. Ziziphus mucronata samples 13-(BUFFALOTHORN/NC) 
and 156-(BUFFALOTHORN/NC) originate from the Northern Cape and Samples 158-
(BUFFALOTHORN/NW) and 159-(BUFFALOTHORN/NW) originate from the North West 
province. These four samples demonstrate equivalent inhibitory values with the exception of 
investigations against P. aeruginosa and the laboratory strain of C. albicans for honey 
sample 13-(BUFFALOTHORN/NC). 
City mix Samples 4-(CITYMIX/WC) and 19-(CITYMIX/FS) which originated from the Western 
Cape and Free State provinces respectively had similar antimicrobial efficacy with the 
exception of studies against the clinical strain of C. albicans and the methicillin and 
gentamicin resistant S. aureus strain which was more sensitive to 19-(CITYMIX/FS) with an 
MIC of 6.25% contrasting to sample 4-(CITYMIX/WC) which had an MIC of 25.00% and 
12.5% for the respective strains. 
Strandveld samples 9-(STRANDVELD/WC), 11-(STRANDVELD/WC), 24-
(STRANDVELD/WC), and 44-(STRANDVELD/WC) originate from different areas in the 
Western Cape. However, sample 44-(STRANDVELD/WC) from Albertina exhibited 
enhanced antimicrobial efficacy comparatively. Sample 9-(STRANDVELD/WC), 11-
(STRANDVELD/WC), and 24-(STRANDVELD/WC) demonstrated no significant antimicrobial 
activity with the exception of 9-(STRANDVELD/WC), which resulted in an MIC of 6.25% 
against the P. aeruginosa strain. 
Acacia mellifera sample 14-(HOOKTHORN/NC) from the Northern Cape and Sample 50-
(HOOKTHORN/WC) from the Western Cape displayed equivalent inhibitory values of MICs 
of 50.00% for all pathogens tested. 
2.3.3 Comparison of monofloral honeys to polyfloral honeys 
The antimicrobial efficacy of honeys from a perceived monofloral source was comparatively 
evaluated with honeys perceived to have been obtained from a polyfloral source. City mix 
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samples {4-(CITYMIX/WC) and 19-(CITYMIX/FS)} both displayed superior antimicrobial 
efficacy with mean MIC values of 6.25% against S. aureus, MRSA, P. aeruginosa and S. 
epidermidis. This superior antimicrobial efficacy is diminished when city mix is combined with 
tuart gum 5-(CITYMIXTUART/WC) displaying a mean MIC value of 50.00%±00. Allium cepa 
154-(ONION/WC) demonstrated a mean MIC value of 50.00% against all pathogens and 
sample 15-(ONION/WC) displayed an enhanced mean MIC of 15.28±5.51%. Despite this, 
the Allium cepa and Erica spp. sample {34-(ONION/FYNBOS)} demonstrated a mean MIC of 
47.22%. Two Erica spp. {37-(FYNBOS/WC) and 40-(FYNBOSGUARRI/WC)} from Stanford 
were analysed. The monofloral sample 37-(FYNBOS/WC) exhibited better antimicrobial 
activity when compared to the polyfloral sample 40-(FYNBOSGUARRI/WC) which was a 
combination of Erica spp. and Euclea racemosa. A large variation in antimicrobial activity 
exists within monofloral Erica spp. samples. In combination with Eucalyptus conferruminata 
{sample 35-(FYNBOSEC/WC)} moderate antimicrobial activity was noted. Improved 
antimicrobial activity was noted in combination with Morella cordifolia (38-
(WASBESSFYNBOS/WC). Two monofloral Eucalyptus cladocalyx samples {(21-
(SUGARGUM/WC) and 39-(SUGARGUM/WC)} produced MIC values of 50.00 and 25.00%. 
Antimicrobial activity was noted in polyfloral sample 36-(EUCLADFICI/WC) whereby sugar 
gum was combined with Eucalyptus ficifolia. When Eucalyptus cladocalyx was combined 
with Erica spp. 8-(ECFYNBOS/WC) no marked improvement could be noted. Saligna gum 
47-(SALIGNAGUM/KZN) and Karri gum 46-(KARRIGUM/WC) displayed an average MIC of 
50% against all pathogens. Antimicrobial activity in mixed gums was substantially enhanced. 
Sample 18-(MIXEDGUM/FS) displayed an MIC of 6.25% of all strains with the exception of 
the Candida spp.  
When examining the data from this study, the general trend seems to be that polyfloral 
honey has better activity than monofloral sources. This is not surprising as polyfloral sources 
could offer a far more complex range of chemical compounds, which might target the 
microbial organisms at multiple target sites and thus cause cell death or inhibition by 
differing mechanisms. 
2.3.4 Honeys antimicrobial efficacy due to age 
Many compounds in honey are unstable and their structures may transform during honey 
maturation and storage (Kaskoniene and Venskutonis, 2010). An example of the possibility 
of structural change was explored by Irish and co-workers (2011) who investigated the 
stability of honeys and revealed that non-peroxide honeys derived from clover, mixed flora 
and paperbark as well as samples from L. liversidgei either remained stable or declined with 
time. In addition, it was demonstrated that honey samples derived from another species; L. 
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polygalifolium, increased in antimicrobial activity. It is postulated that non-peroxide activity 
may increase in time as a resulting increase of methylglyoxal as an effect of the Maillard 
reaction (Irish et al, 2011). Allen and co-workers (1991) research conflicts, having reported 
that there is no correlation between the age of honey and its antimicrobial effects. The 
instability of the enzyme glucose oxidase may possibly have an effect on peroxide honeys. 
The stability and antimicrobial potency of honey over time has to be quantified to establish a 
shelf-life in honeys that have the potential to be commercialised. Honeys with phenomenal 
antimicrobial activity that degrade over time should not be excluded from being used 
clinically, as the efficacy of pharmaceutical products also diminishes with time. However, a 
suitable shelf-life could be established which would overcome this.  
 
The MIC values of honey samples collected prior to 2011 are given in Table 2.5. In this study 
it was confirmed that Erica spp., allium cepa and Eucalyptus tereticornis older samples were 
less efficacious than newer samples. Acacia mellifera, Eucalyptus cladocalyx, Eucalyptus 
grandis, Citrus spp. displayed enhanced antimicrobial activity on ageing. Of the six Manuka 
honey samples analysed, two samples from 2008 and 2011 produced MIC values of 15.97 
and 15.28 respectively. Two samples from 2008 and 2011 displayed mean MIC values of 
20.14% and 20.17% respectively, thus proving that in this study on Manuka honey age was 
not a considerable factor affecting the antimicrobial efficacy of honey. 
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Table 2.5: Mean inhibitory concentration (% inhibition) of samples collected prior to 2011. 
 
REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC2223 
P. aeruginosa 
ATCC9027 
C. albicans 
ATCC 
10231 
C. albicans 
clinical MEAN MIC 
60-(YELLOWBOX/WC) 50.00 50.00 25.00 25.00 50.00 50.00 50.00 50.00 50.00 
44.44±11.0
2 
61-(STRANDVELD/WC) 25.00 25.00 12.50 12.50 12.50 25.00 12.50 50.00 50.00 
25.00±15.3
1 
62-(SUGARGUM/WC) 12.50 12.50 12.50 12.50 12.50 6.25 6.25 50.00 50.00 
20.31±18.5
3 
64-(CITRUS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 
30.56±11.0
2 
69-(OLIVEFYN/SC) 50.00 50.00 25.00 25.00 50.00 50.00 50.00 50.00 50.00 
44.44±11.0
2 
80-
(FORESTREDGUM/WC) 
25.00 25.00 25.00 25.00 6.25 25.00 6.25 50.00 50.00 
26.39±15.5
6 
86-(LITCHI/MP) 50.00 50.00 50.00 50.00 25.00 25.00 25.00 50.00 50.00 
41.67±12.5
0 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC2223 
P. aeruginosa 
ATCC9027 
C. albicans 
ATCC 
10231 
C. albicans 
clinical MEAN MIC 
90-(FYNBOS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 
30.56±11.0
2 
94-(HOOKTHORN/NC) 12.50 12.50 12.50 12.50 12.50 12.50 12.50 25.00 25.00 15.28±5.51 
106-(ONION/WC) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
109-(FYNBOS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 
30.56±11.0
2 
116-(FYNBOS/SC) 25.00 50.00 25.00 25.00 25.00 25.00 50.00 50.00 50.00 
36.11±13.1
8 
117-
(WILDFLOWERS/GP) 
25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 
30.56±11.0
2 
119-
(BUFFALOTHORN/NW) 
25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 
30.56±11.0
2 
123-
(SALIGNAGUM/KZN) 
25.00 25.00 25.00 25.000 12.50 12.50 12.50 50.00 50.00 
26.39±14.5
8 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC2223 
P. aeruginosa 
ATCC9027 
C. albicans 
ATCC 
10231 
C. albicans 
clinical MEAN MIC 
135-(FYNBOS/WC) 25.00 25.00 25.00 25.00 25.00 25.00 25.00 50.00 50.00 
30.56±11.0
2 
139-(BLUEBUSH/NW) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
142-
BUFFALOTHORN/NW) 
50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
144-(FYNBOS/WC) 12.50 50.00 12.50 12.50 12.50 12.50 12.50 50.00 50.00 
25.00±18.7
5 
145-(COSMOS/NP) 25.00 50.00 50.00 50.00 25.00 6.25 12.50 50.00 50.00 
35.42±18.2
2 
146-(REDSYRING/LIM) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
148-(ALOE/NP) 50.00 50.00 50.00 25.00 12.50 6.25 12.50 50.00 50.00 
34.03±19.5
4 
149-(HOOKTHORN/NP) 50.00 50.00 50.00 50.00 50.00 25.00 50.00 50.00 50.00 47.22±8.33 
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REFERENCE CODE 
S. aureus 
ATCC 
25923 
S. aureus 
clinical 
S. aureus 
(MRSA) 
43300 
S. aureus 
(MRSA) 
clinical 
S. aureus 
(M & G)* 
ATCC 
33592 
S. epidermidis 
ATCC2223 
P. aeruginosa 
ATCC9027 
C. albicans 
ATCC 
10231 
C. albicans 
clinical MEAN MIC 
150-(COMBRETUM/GP) 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00±0.00 
155-(CATTHORN/EC) 50.00 50.00 50.00 50.00 50.00 50.00 6.25 50.00 50.00 
45.14±14.5
8 
96-(MANUKA/NZ) 
6.25 6.25 6.25 6.25 6.25 25.00 6.25 50.00 50.00 
15.97± 
19.29 
97-(MANUKA/NZ) 
6.25 6.25 6.25 6.25 6.25 25.00 25.00 50.00 50.00 
20.14±18.6
9 
147-(MANUKA/NZ) 
50.00 50.00 25.00 25.00 12.50 12.50 12.50 50.00 50.00 31.94± 17.8 
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2.4 Conclusions 
 
 The antimicrobial activity of 55 honey samples collected in 2011 demonstrated % 
inhibition ranging from 10.42-50.00%. 
 The control, Manuka honeys, displayed % inhibition ranging from 15.28-41.67%. 
 The greatest antimicrobial activity was exhibited by honey sample 16-(FYNBOS/WC) 
which displayed a mean MIC of 10.42±8.27%. 
 Nine honey samples displayed a mean MIC value that was superior to that of the 
lowest mean MIC value exhibited by the control, Manuka honey. 
 Polyfloral honey displayed better activity than monofloral sources. 
 An enhanced antimicrobial activity was displayed on ageing, in certain samples. 
 Results of this study confirm that SA honeys do possess antimicrobial efficacy. 
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CHAPTER 3 
ANTIBIOTIC-HONEY COMBINATION STUDIES 
 
3.1 Introduction 
 
Infectious diseases are a multifaceted interplay between the pathogen, the physiological and 
immunological status of the host and the environment (Guillemot, 1999). The increased, 
improper and irrational utilisation of antibiotics by prescribers has precipitated towards world-
wide antibiotic resistance. Prescribers using treatment regimens based on empiric therapy 
as opposed to definitive therapy has greatly contributed to antibiotic resistance. Furthermore, 
patients also contribute to antibiotic resistance by improper usage, such as missing doses 
and not completing the entire course of antibiotics as prescribed. In the current era of 
vaccines and antibiotics, one would expect that infectious diseases be under control, 
however, in many developing countries they continue to be principle causes of mortality at 
an alarming rate (WHO, 1999).  
 
This has financial consequences as there may be a need for further laboratory testing, 
utilisation of more drugs, longer treatment duration, and increased hospitalisation (Nyasulu 
et al., 2012). Conventional treatment options may be more costly and ease of access to 
these options may prove arduous. Apart from resistance being a major concern, antibiotics 
themselves, demonstrate adverse effects such as hypersensitivity or allergic reactions, 
nausea, ototoxicity, immunosuppression and destruction of good intestinal flora (Al-Jabri, 
2005). This has resulted in research efforts to determine if complementary and alternative 
medication (CAM) such as honey, could be an effective antimicrobial agent when 
incorporated or utilised with conventional antimicrobials as a pharmaceutical healthcare 
option. These preparations should display low toxicity and have a little to no environmental 
impact (Darwish and Aburjai, 2010).  
 
Infections with antibiotic resistant pathogens are a major healthcare concern. Despite this, 
there are limited new antibiotics in development, as seen in the decreased numbers of 
regulatory approvals. The lack of profitability and the challenge of finding novel targets for 
antibiotics in pathogens, contribute to the deficiency of new antibiotics in development. 
Resistance generally occurs via target modification, efflux, immunity and bypass, and 
enzyme catalysed destruction (Wright, 2010). The persistent use of antibiotics results in 
mutation of the pathogens culminating in possible resistance to the antibiotic. 
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Gallocatechins, Salivia milttiorhiza, curcuminoids, carnosic acid, berberine, aqueous crude 
khat extracts, and diterpenes from Lycopus europaues are only some of the natural products 
currently being investigated for possible combination therapy with antibiotics (Hemaiswarya 
et al., 2008; Jenkins and Cooper, 2012). CAM agents could also be economically 
advantageous, may possess superior patient acceptability and are not stringently regulated. 
In practice, patients often utilise CAM with conventional medication concurrently. It is 
postulated that honey possesses chemical components similar to that of antibiotics 
(Brudzynski and Lannigan, 2012). Natural products for medicinal use present an 
innumerable variety of chemical structures which may serve as lead molecules whose 
activities can be further improved through combinations with chemicals and by synthetic 
chemistry. Several natural products are selected for their antimicrobial effects and are 
utilised in combination with conventional antibiotics. There are numerous advantages of 
utilising natural products in combination with antibiotics. Natural products have different 
mechanisms of action which could either enhance the antibiotics mechanism of action or 
provide an additional mechanism, resulting in dose reduction, quicker onset of action and a 
decreased duration of therapy. This could significantly decrease adverse side effects that 
are usually associated with high doses of antibiotics, ultimately delaying or preventing 
antimicrobial resistance (Hemaiswarya et al., 2008). For example when honey and bovine 
milk are used in combination there was a quicker onset of action in comparison to the 
individual components (Al-Jabri, 2005). SA honey may potentially be synergistic, additive or 
indifferent with conventional antibiotics, as certain SA honeys demonstrate noteworthy 
antimicrobial potency as demonstrated in Chapter 2 of this research report. 
 
In this Chapter, combination studies were undertaken whereby the conventional 
antimicrobials; ciprofloxacin, gentamicin and antifungal agents; amphotericin B and nystatin 
were combined with a selection of SA honeys to investigate whether synergism, additive or 
antagonistic interactions were evident.  
3.2 Materials and methods 
3.2.1 Honey samples 
To evaluate the possible synergistic effects of SA honey with conventional antibiotics, five 
honey samples were selected based on their enhanced antimicrobial efficacy as observed in 
Chapter 2. Honey samples utilised in this study included; 16-(FYNBOS/WC), 18-
(MIXEDGUM/FS), 19-(CITYMIX/FS), 26-(FYNBOS/WC) and 41-(INDIGENOUS/WC). 
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3.2.2 Pathogens and antibiotics 
Ciprofloxacin and gentamicin were selected as test antibiotics for this study. Similarly, two 
antifungals (nystatin and amphotericin B) were also selected. Antibiotics and antifungals 
were purchased from Sigma Aldrich. Ciprofloxacin and gentamicin were tested against 
Pseudomonas aeruginosa (laboratory – ATCC 9027) and Staphylococcus aureus (laboratory 
- ATCC 25923). Nystatin and amphotericin B were tested against Candida albicans 
(laboratory – ATCC 10231). Stock solutions of antibiotics were appropriately prepared with 
an antibiotic starting concentration of 0.01mg/mL and an antifungal starting concentration of 
0.001 mg/mL. These antimicrobial agents are classified as broad-spectrum agents and were 
selected because they offer greater pathogen coverage. This will subsequently elucidate the 
synergistic, additive or antagonistic effects of combination with honey over a wider range of 
pathogens and thus offer a more holistic account of these effects. 
3.2.3 MIC determination 
 
The microtitre plate microdilution method was used to investigate antimicrobial activity of 
honey combined with conventional antimicrobials (ciprofloxacin, gentamicin for bacteria and 
nystatin and amphotericin B for yeasts). Methods were adapted from National Committee for 
Clinical Laboratory Services guidelines (NCCLS, 2003) with modifications catering for the 
viscosity of honey. Figure 3.1 is a typical 96-well microtitre plate that was adapted for this 
study. This method is advantageous as it is timeous, economical and the results are 
reproducible. When using Figure 3.1 as a template, under aseptic conditions (laminar flow), 
all wells marked from row B-H of the 96-well microtitre plate (NUNC, Denmark) were filled 
with 100 µL of sterilized deionised water. Wells A1 – A3 were filled with 200 µl of 50% 
honey. Wells A4-A6 were filled with 100 µl of antibiotic and 100 µl of sterile deionised water. 
Wells A7-A9 were filled with 100 µl of antibiotic and 100 µl of 50% honey solution. Serial 
doubling dilutions were then performed. The microtitre plates were then removed from the 
laminar flow unit. A 100 µl of TSB inoculated with the respective pathogen (1:100) was 
subsequently added to each well. A Gram-negative reference strain (P. aeruginosa NCTC 
9027), Gram-positive reference strain (S. aureus ATCC 25923) and yeast (C. albicans ATCC 
10231) were selected to test the antimicrobial efficacy of honey samples in combination with 
conventional antibiotics and antifungals. The microtitre plates inoculated with bacterial 
pathogens were incubated at 37 °C for 24 hours whereas the microtitre plates inoculated 
with the yeast were incubated for 48 hours at 37 °C. Negative controls were attained by 
utilising a honey/drug free well (A10-A12).  
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Figure 3.1: Serial dilutions utilising a 96-well microplate adapted from NCCLS guidelines 
(2003) with modifications catering for the viscosity of honey. 
 
A streak plate of the culture was also incubated, to ensure purity of the culture by 
identification of single colonies. To determine if the media utilised was sterile, the media was 
left overnight at room temperature. A visual inspection for contamination i.e. turbidity, was 
used to confirm the sterility of the media. 
 
After appropriate incubation periods, 40 µl of iodonitrotetrazolium violet (Sigma-Aldrich) 
(INT) indicator was added to each well to improve visual identification of microbial growth or 
inhibition of test pathogens. INT indicator solution was prepared by weighing 0.04 g of INT 
and adding this to 100 mL of sterile distilled water. Due to the fact that INT is insoluble in 
cold water, it was placed in a shaker incubator at 55 °C for 30 minutes. It was then stored in 
the refrigerator at 4 °C. The colourless tetrazolium salt is reduced to a red colour by acting 
as an electron acceptor by metabolically active micro-organisms (Eloff, 1998). Where there 
was no microbial growth, INT remained colourless. 
 
The MIC was defined as the lowest concentration of honey, antibiotic or honey-antibiotic 
combination to inhibit visible growth. A light box was utilised to facilitate recognition of colour 
differences. 
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3.2.4 Determination of Fractional Inhibitory Concentration (FIC) Index 
 
The in vitro antimicrobial interaction was assessed utilising the FIC index (ΣFIC). The Loewe 
additivity zero-interaction theory forms the basis for FIC determination. It is hypothesised 
that because a drug cannot interact with itself, the effect of self-drug combination will always 
be additive depicting a FIC value of 1. This is a prelude to the hypothesis that less or more 
drug would be required in order to produce the same effects as the drug alone (Meletiadis et 
al., 2010). The FIC value was used to establish if honey and antibiotics are synergistic, 
additive, indifferent or antagonistic when combined together and were calculated using 
Equation 1 and 2 which were adapted from Van Vuuren and Viljoen (2011). The ΣFIC is a 
summation of the FIC of the individual components being analysed. The FIC of each 
component was determined by dividing the MIC of the agent when used in combination over 
the MIC of the agent when utilised alone (Equations 1 and 2). The ΣFIC was used to assess 
interactive antimicrobial effects for honey and antibiotic combinations.  
 
     Equation 1  
 
 
     Equation 2   
 
    
Where, (a) represents the honey, (b) the respective antimicrobial and (i) and (ii) represents 
the honey and the antimicrobial in combination 
The sum of the FIC, known as the FIC index is thus calculated as: 
 
ΣFIC = FIC (*i)+ FIC (*ii)      Equation 3 
 
The FIC index was used to determine the correlation between the honey and conventional 
agent. An FIC index ≤0.5 is indicative of synergism, whereas a FIC index > 4.0 is an 
indication of antagonism. Additive effects are exhibited when the FIC index ranges from > 
0.5-1.0. Indifferent effects are depicted when the calculated FIC is >1.0 and ≤4.0 (Van 
Vuuren and Viljoen, 2011). Synergism would occur when honey and antibiotics used in 
combination have enhanced effects in comparison to being used individually, greater than 
additive effects. If the combined effects result in deterioration of activity, the combination 
would then be classified as antagonistic. 
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3.3 Results and discussion 
Table 3.2-3.5 describes honey-antibiotic combinations tested against each pathogen listing 
the MIC of the antibiotic, honey and the honey-antibiotic combination, FIC value and 
interpretation of the FIC value.  
3.3.1 Combination with ciprofloxacin 
S. aureus is one of the most common wound pathogens frequently isolated in wounds and is 
the pathogen responsible for a multitude of acute and chronic skin infections (Muller et al., 
2013). Resistance of ciprofloxacin to S. aureus especially MRSA has increased to over 90% 
(Limoncu et al., 2003). Although a lack of synergy was demonstrated with ciprofloxacin in 
combination with honey, additive effects were seen. These additive effects were 
demonstrated when honey samples 18-(MIXEDGUM/FS), 19-(CITYMIX/FS), 41-
(INDIGENOUS/WC) were combined with ciprofloxacin and tested against S. aureus. 
Similarly, honey samples 16-(FYNBOS/WC), 26-(FYNBOS/WC) and 41-(INDIGENOUS/WC) 
displayed additive effects with ciprofloxacin against P. aeruginosa. Additive interactions may 
prove to be valuable in the prevention or delay of further resistance.  
Reports of resistance to ciprofloxacin have been documented with mechanisms of resistance 
to ciprofloxacin generally as a result of mutations of topoisomerase II, topoisomerase IV and/ 
or activation of drug efflux pump (Limoncu et al., 2003). Ranjbar and co-workers (2011) 
reported an incidence of 65% resistance of ciprofloxacin to 70 isolated strains of P. 
aeruginosa in infected burn wounds (Ranjbar et al, 2011). Valencia and co-workers reported 
increases in quinolone resistant P. aeruginosa in infected leg ulcers (Valencia et al., 2004). 
In this study, two synergistic combinations were demonstrated for honey samples 18-
(MIXEDGUM/FS) and 19-(CITYMIX/FS) in combination with ciprofloxacin against P. 
aeruginosa (Table 3.1). The samples displayed a ΣFIC of 0.38 and 0.50 respectively 
confirming their synergistic action. Ciprofloxacin (µg/mL): Honey (%) ratios utilised in these 
synergistic combinations were 0.00375:0.0375 for 18-(MIXEDGUM/FS) and 0.005: 0.05 for 
19-(CITYMIX/FS). The results corroborates with a previous study whereby enhanced activity 
of ciprofloxacin was also seen in combination with honey against P. aeruginosa (Abd-el et 
al., 2007). 
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Table 3.1: MIC and ΣFIC values of honey samples with ciprofloxacin. 
PATHOGEN HONEY 
SAMPLE 
MIC  FIC 
CIPROFLOXACIN   
µG/ML 
HONEY 
% 
COMBINATION 
CIPROFLOXACIN (µG/ML): 
HONEY (%) 
ΣFIC INTERPRETATION 
S. aureus 
(laboratory 
- ATCC 
25923) 
16-
(FYNBOS/
WC) 
0.313 25.00     0.313                        3.13 1.13 Indifferent 
18-
(MIXEDGU
M/FS) 
0.313 25.00     0.156                        1.56 0.56 Additive 
19-
(CITYMIX/F
S) 
0.313 25.00     0.156                        1.56 0.56 Additive 
26-
(FYNBOS/
WC) 
0.313 25.00     0.313                        3.13 1.13 Indifferent 
41-
(INDIGENO
US/WC) 
0.313 25.00     0.156                        1.56 0.56 Additive 
P. 
aeruginosa 
(laboratory 
– ATCC 
9027) 
16-
(FYNBOS/
WC) 
0.008 12.50     0.005                        0.05 0.67 Additive 
18-
(MIXEDGU
M/FS0 
0.010 25.00     0.00375                    
0.0375 
0.38 Synergistic 
19-
(CITYMIX/F
S) 
0.010 25.00     0.005                        0.05 0.50 Synergistic 
26-
(FYNBOS/
WC) 
0.008 25.00     0.010                         
0.100 
1.33 Additive 
41-
(INDIGENO
US/WC) 
0.010 25.00     0.010                         
0.100 
1.00 Additive 
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3.3.2 Combination with gentamicin 
In this study, synergistic effects with gentamicin against S. aureus were observed with honey 
samples; 16-(FYNBOS/WC), 18-(MIXEDGUM/FS), 19-(CITYMIX/FS), 26-(FYNBOS/WC) 
and 41-(INDIGENOUS/WC) (Table 3.2). Synergism of gentamicin with honey samples 16-
(FYNBOS/WC) and 19-(CITYMIX/FS) was also observed against P. aeruginosa. The 
synergy demonstrated by all five honey samples in combination with gentamicin against S. 
aureus is noteworthy. Furthermore, additive effects of gentamicin with honey samples 18-
(MIXEDGUM/FS), 26-(FYNBOS/WC) and 41-(INDIGENOUS/WC) against P. aeruginosa 
were demonstrated. As previously mentioned, although not as desirable as synergy, additive 
effects could curb resistance mechanisms. 
P. aeruginosa is an important pathogen which is usually acquired nosocomially and is a 
serious cause of infection (Abd-el et al., 2007). This pathogen is of clinical significance as it 
can result in death, particularly in the immunocompromised and burn patients. It is also 
known to be resistant to antimicrobial therapy (Karakoc and Gerceker, 2001, Mullai and 
Menon, 2005). A number of P. aeruginosa strains have been reported to show resistance to 
several antibiotics and serious P. aeruginosa infections are now generally being treated with 
antibiotic multitherapy (Abd-El et al., 2007; Jayaram et al., 2010). These antibiotics usually 
have different targets to enhance antibacterial activity. Two of the five honeys namely; 16-
(FYNBOS/WC) and 19-(CITYMIX/FS) demonstrated synergy in combination with gentamicin. 
In a previous study, Karayil and co-workers (1998) successfully reported the synergistic 
effect of Indian honey with gentamicin, amikacin and ceftazidime against six multi-drug 
resistant Pseudomonas strains utilising the broth dilution method. Synergism was not 
produced against the eight Klebsiella strains tested (Karayil et al., 1998).  
Al-Jabri (2005) reported that honey and gentamicin in combination, achieved a better 
bactericidal effect than when compared to the antibiotic and the honey tested individually (Al-
Jabri, 2005). The study tested 30 Omani honeys, of which one sample demonstrated an 
enhanced activity of gentamicin against S. aureus by 22% in 30 minutes (Al-Jabri, 2005). 
Synergism between gentamicin and honey was not reproduced in a study performed by 
Jenkins and Cooper (2012). This was possibly due to the fact that different honeys from 
different geographical regions were studied (Jenkins and Cooper, 2012).  
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Table 3.2: MIC and ΣFIC values of honey samples with gentamicin. 
PATHOGEN HONEY SAMPLE MIC  FIC 
GENTAMICIN 
µG/ML 
HONEY
% 
COMBINATION 
GENTAMICIN (µG/ML): HONEY 
(%) 
ΣFIC INTERPRETATION 
S. aureus 
(laboratory - 
ATCC 
25923) 
16-(FYNBOS/WC) 0.156 25.00  0.039               0.39 0.27 Synergistic 
18-(MIXEDGUM/FS) 0.156 25.00  0.039               0.39 0.27 Synergistic 
19-(CITYMIX/FS) 0.156 25.00  0.039               0.39 0.27 Synergistic 
26-(FYNBOS/WC) 0.156 25.00         0.039               0.39 0.27 Synergistic 
41-
(INDIGENOUS/WC) 
0.156 25.00  0.039               0.39 0.27 Synergistic 
P. 
aeruginosa 
(laboratory 
– ATCC 
9027) 
16-(FYNBOS/WC) 0.625 25.00  0.156               1.56 0.31 Synergistic 
18-(MIXEDGUM/FS) 0.625 25.00  0.313               3.13 0.63 Additive 
19-(CITYMIX/FS) 0.625 25.00  0.235               2.35 0.47 Synergistic 
26-(FYNBOS/WC) 0.625 25.00         0.313               3.13 0.63 Additive 
41-
(INDIGENOUS/WC) 
0.625 25.00         0.313               3.13 0.63 Additive 
 
3.3.3 Combination with nystatin 
Synergism of nystatin with the 16-(FYNBOS/WC) honey sample against C. albicans was 
noted whereas additive effects of nystatin with honey samples were observed with 
combinations containing 18-(MIXEDGUM/FS), 19-(CITYMIX/FS), 26-(FYNBOS/WC) and 41-
(INDIGENOUS/WC) honeys. Nystatin is a polyene antifungal agent which acts by binding 
with ergosterol in fungal membranes resulting in changes to the permeability of the 
membrane consequently leading to intracellular leakage of components causing cell death 
(Ashley et al., 2006).  
Candida infections are on the rise as a result of the utilisation of broad-spectrum antibiotics 
and the increased number of patients that are immunocompromised as a result of the HIV 
epidemic (Álvaro-Meca et al., 2013). Owing to this fact, a CAM with possible antifungal 
effects such as honey would curb resistance when used in combination with a conventional 
honey.  
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Table 3.3: MIC and FIC values of honey samples with nystatin. 
PATHOGEN HONEY SAMPLE MIC  FIC 
NYSTATIN 
µG/ML 
HONEY 
% 
COMBINATION 
NYSTATIN (µG/ML): HONEY (%) 
ΣFIC INTERPRETATION 
C. albicans 
(laboratory 
– ATCC 
10231) 
16-(FYNBOS/WC) 0.00625 12.50      0.00156         1.56 0.37 Synergistic 
18-(MIXEDGUM/FS) 0.009375 25.00      0.00625         6.25 0.92 Additive 
19-(CITYMIX/FS) 0.00625 25.00      0.00625         6.25 1.25 Additive 
26-(FYNBOS/WC) 0.00625 25.00      0.00312         3.13 0.62 Additive 
41-
(INDIGENOUS/WC) 
0.00625 25.00      0.00625         6.25 1.25 Additive 
 
3.3.4 Combination with amphotericin B  
In this study additive effects of amphotericin B with honey samples 16-(FYNBOS/WC); 18-
(MIXEDGUM/FS), 19-(CITYMIX/FS), 26-(FYNBOS/WC) and 41-(INDIGENOUS/WC) were 
observed (Table 3.4). 
Amphotericin B exerts its activity similarly to nystatin. This is achieved by forming complexes 
with sterols, mainly ergostreol, increasing permeability, resulting in intracellular leakage of 
components and cell mortality. Amphotericin B is a broad-spectrum antifungal agent and is 
generally the drug selected for treating systemic mycoses (Ashley et al., 2006, SAMF, 2012) 
Its indications include; disseminated candiasis, cryptococcis, mucormycosis, histoplasmosis, 
extracutaneous sporotrichhosis, blastomycosis and leishmaniasis (SAMF, 2012).  
Antifungal agents are often associated with toxicities. Additive interactions with honey may 
facilitate a dose reduction in the antifungal utilised, thereby aiding to decrease adverse 
effects and toxicities associated with antifungal agents. A major concern is the economic 
impact of treating with newer antifungal agents due to their costly nature (Munoz et al., 
2010). Honey may provide an economical advantage as it is by far, a cheaper option. 
Additive interactions maybe helpful to reduce the financial burden associated with fungal 
infections.  
 
 
 
 
73 
 
Table 3.4: MIC and FIC values of honey samples with amphotericin B. 
PATHOGEN HONEY SAMPLE MIC  FIC 
AMPHOTERICIN B 
µG/ML 
HONEY
% 
COMBINATION 
NYSTATIN (µG/ML): HONEY 
(%) 
ΣFIC INTERPRETATION 
C. albicans 
(laboratory 
– ATCC 
10231) 
16-(FYNBOS/WC) 0.0002 1.56       0.0002           0.20 1.13 Additive 
18-(MIXEDGUM/FS) 0.0002 25.00       0.0002           0.20 1.00 Additive 
19-(CITYMIX/FS) 0.0002 25.00       0.0002           0.20 1.00 Additive 
26-(FYNBOS/WC) 0.00039 25.00       0.00039         0.39 1.02 Additive 
41-
(INDIGENOUS/WC) 
0.00039 25.00       0.00039         0.39 1.02 Additive 
 
3.3.5 Overview 
Honey is a beneficial natural product to be investigated as it has been identified to be a 
complex substance comprising numerous components with antibacterial properties such as 
methylglyoxal and hydrogen peroxide. Antibacterial properties of honey can be attributed to 
various aspects, producing a bactericidal effect (Mathews and Binnington, 2002).  
Physicochemical properties such as pH, moisture content and sugar content further 
contribute to the antibacterial properties. Honey also promotes wound healing and can act 
as a highly viscous physical barrier protecting the wound surface from becoming colonised 
and invaded by potential pathogens.  
This research investigated thirty combinations of honey and antibiotic, which revealed ten 
synergistic combinations, eighteen additive combinations, two indifferent combinations and 
most importantly, no antagonistic combinations. The most effective synergistic combinations 
were demonstrated by all five honeys tested in combination with the antibiotic gentamicin 
against S. aureus. Synergy was also observed in ciprofloxacin combined with 18-
(MIXEDGUM/FS) and 19-(CITYMIX/FS) against P. aeruginosa; gentamicin combined with 
16-(FYNBOS/WC) and 19-(CITYMIX/FS) against P. aeruginosa; nystatin combined with 16-
(FYNBOS/WC) against C. albicans. No antagonistic interactions were demonstrated.  
Synergistic combinations show a decrease in the MIC value of the antibiotic when combined 
with honey. This would allow for dose reduction of the antibiotic thereby minimising possible 
side effects, reducing treatment costs and providing a therapeutic option with greater 
antimicrobial potential. In addition, the potential risk of antimicrobial resistance is thought to 
be minimised with the utilisation of combination therapy.  
74 
 
Other studies reporting synergistic interactions of honey and antibiotics include the study by 
Jenkins and Cooper (2012) where Manuka honey combined with imipenem, tetracycline and 
mupirocin were tested against MRSA (Jenkins and Cooper, 2012).  
Muller and co-workers investigated the combination of Medihoney® and rifampicin. 
Rifampicin is utilised in the treatment of TB, leprosy, brucellosis and resistant Staphylococcal 
infections (SAMF, 2012). The study revealed that the honey-rifampicin combination was 
synergistic against MRSA and clinical isolates (Muller et al., 2013). A key observation was 
that if MRSA was treated with rifampicin only, the pathogen rendered resistance hastily. 
However, the in vitro combination treatment did not result in rifampicin-resistant MRSA 
(Muller et al., 2013). This could be due to the complex nature of honey and its numerous 
components offering varying modes of action.  
 
Methylglyoxal is postulated to be the main component contributing to antibacterial activity, 
however research has indicated that methylglyoxal individually does not produce a 
synergistic effect in combination with rifampicin while Medihoney® in combination with 
rifampicin produced a synergistic effect (Muller et al., 2013). This confirms that the numerous 
components of honey together produce an antibacterial effect.  
Although this was entirely an in vitro study, the ramifications cannot be underestimated. 
There is potential to develop a therapeutically effective combination therapy to improve 
bacteriostatic and bactericidal mechanisms to rapidly eradicate infections. In addition, it is 
hypothesised that this approach could prevent or delay the global concerns of antimicrobial 
resistance. Infections with antibiotic resistant pathogens progress rapidly and are becoming 
increasingly difficult to treat. These infections are associated with morbidity and mortality. 
Despite this, there are limited novel antibiotics on the horizon. Resistance is more easily 
developed with therapeutic utilisation of a single agent in comparison to multiple agents, 
hence, a combination of agents is required. Insurmountable benefits arise from combining a 
conventional antimicrobial with a complementary antimicrobial agent. Results from this study 
emphasise the potential of combining honey with a conventional antibiotic as no antagonistic 
or deleterious effects were demonstrated.  
 
3.4 Conclusions 
 
 Synergism was demonstrated between honeys; 18-(MIXEDGUM/FS) and 19-
(CITYMIX/FS) with the broad-spectrum antibiotic ciprofloxacin against P. aeruginosa. 
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 Synergistic effects with gentamicin against S. aureus were observed with honey 
samples; 16-(FYNBOS/WC), 18-(MIXEDGUM/FS), 19-(CITYMIX/FS), 26-
(FYNBOS/WC) and 41-(INDIGENOUS/WC). 
 Two of the five honeys namely; 16-(FYNBOS/WC) and 19-(CITYMIX/FS) 
demonstrated synergy in combination with gentamicin 
 Synergistic effects between the honey sample 16-(FYNBOS/WC) and the antifungal 
nystatin were elucidated against C. albicans. 
 The combination of Amphotericin B with the selected SA honeys yielded only additive 
effects. 
 No antagonistic interactions were observed for all combinations tested.  
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CHAPTER 4 
PHYSICOCHEMICAL PROPERTIES 
 
4.1 Introduction 
 
Honey comprises glucose and fructose as majority components and a much lower water 
component thus resulting in a notable interaction between these sugars and the water 
molecules. In turn, this results in fewer free water molecules available for microbial growth 
(Olaitan et al., 2007). These properties additionally contribute to honeys wound healing 
characteristics. The moist environment provided by honey promotes wound healing by 
stimulating tissue regrowth and anti-inflammatory effects are also observed (Molan (a), 
1999). The viscous nature of honey provides a protective barrier to prevent infection and 
cross contamination by sealing the wound (Molan, 2002). Fibroblast activity in terms of 
migration, proliferation, and organisation of collagen requires a mildly acidic wound 
environment (Lusby et al., 2002). This activity may be optimised and maintained by the pH of 
honey which aids in achieving this type of environment. 
The chemical constituents contribute to the physicohemical properties of honey. These 
properties impart on to honey its characteristic quality and antimicrobial activities (Manyi-Loh 
et al., 2012). The market demand for selected honey of high therapeutic value has 
increased, creating the need for honey to be standardised and authenticated (Brady et al., 
2004). Globalisation of the honey market also contributes to the need of a standardised 
honey. 
 
The sugars present in honey are as a result of enzymatic action on nectar sucrose 
(Ouchemoukh et al., 2010). The primary sugars contained in honey are glucose and 
fructose. Glucose and fructose are monosaccharides, consisting of a single carbon 
backbone (Olaitan et al., 2007). Honey also contains disaccharides such as maltose, 
sucrose, isomaltose. Furthermore, oligosaccharides are also componential elements.  
 
The water content of honey is also an important variable, which is affected by numerous 
factors. The moist environment offered by honey protects the wound, reduces infection 
rates, debrides necrotic tissue, promotes granulation tissue formation and is an effective 
analgesic (Lusby et al., 2005).  
 
Adulteration of honey with low cost sugar syrup or artificial honey occurs frequently (Wang 
and Li; 2011). Mislabelling of honeys from different geographical areas also poses a 
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problem. Many natural products that are expensive and produced under wide harvesting 
conditions and varying weather patterns are the most prone to adulteration (Mehryar and 
Esmaiili, 2011). Isotope analysis of honey has thus gained increasing popularity to 
authenticate honey and is being recognised as an established method for identifying honey 
adulteration (Chesson et al., 2010). The above-mentioned examples are examples of 
deliberate altering of honey for economic benefits. Despite this, adulteration may also occur 
naturally or due to human error. To cater for the sensitivity of the matter, the word 
“impurification” was utilised in this study. Impurification is a generic term encompassing 
changes to honeys properties either occurring due to natural phenomenon, by human error 
or the more sensitive, deliberate alteration for financial gain (adulteration). 
 
The principle aim of this chapter was to gain knowledge and insight into the chemical 
composition and physical parameters of SA honeys. The accompanied physicochemical 
data acquired in this study is of great importance, as only two studies have investigated the 
physicochemical properties of SA honey (Manyi-loh et al., 2012; Serem and Bester, 2012). 
There is limited data on the physicochemical properties of honey, despite its use in the food 
industry, health products and production of by-products such as wax and propolis. Analysing 
different isotope profiles of SA honeys may provide a “finger print” for each honey sample as 
well as confirmation that the samples are not adulterated or impurified. 
 
4.2 Materials and methods 
4.2.1 Honey samples 
The physicochemical testing was conducted on 36 honey samples of various botanical 
origins which were collected in 2011 based on their availability. None of the honey samples 
showed signs of fermentation or crystallisation prior to analysis of physicochemical 
properties demonstrating that these samples maintained their integrity and were devoid of 
deterioration. Samples were selected on the basis of antimicrobial efficacy (previous 
chapters) and availability.  
4.2.2 Measurement of physicochemical properties 
The water content and sugar content of whole honey was measured with a honey 
refractometer. The pH was determined using a pH meter by dissolving 10 g of whole honey 
in 75 mL of distilled water, following standard AOAC 998.12 protocols (AOAC 998.12, 1999). 
Impurifications of honeys were also quantified. Apparent %C4 impurification, where values 
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greater than 7% were considered questionable was calculated for each honey (White and 
Winters, 1989) utilising Equation 4: 
 
[(δ13C (protein) – (δ13C (whole honey)]*100 / 
[(δ13C (protein) – (-9.7)] 
                                                                                                                       Equation 4 
 
4.3 Results and discussion 
Table 4.1 presents the results obtained for the physicochemical parameters (pH, sugar 
content, moisture content) of the commercially purchased Manuka honey samples tested 
(controls) and Table 4.2 summarises the results of selected SA honeys. The mean MICs are 
included in Table 4.1 and Table 4.2 for reference purposes as the antimicrobial activity of 
honey is known to be a result of its high sugar content, acidic nature and low moisture 
content (Lusby et al., 2005; Mandal et al., 2010). The Manuka honey samples had a water 
content ranging from 17.40-19.00% and a pH range of 4.28-4.44. In addition, the samples 
also displayed a sugar range of 79.25-81.00% and a percentage impurification ranging from 
0.38-14.51 (Table 4.1). Surprisingly, the purchased Manuka honey sample 56-
(MANUKA/NZ) demonstrated substantial impurification. No considerable differences were 
noted between the SA samples and the Manuka honey. 
Table 4.1: Physicochemical properties and mean MIC of Manuka samples tested. 
REFERENCE CODE WATER 
CONTENT 
% 
PH SUGAR 
CONTENT % 
% 
IMPURIFIED/ADULTERED 
MEAN 
MIC (%) 
54-(MANUKA/NZ) 18.50 4.44 79.50 0.95 15.28 
55-(MANUKA/NZ) 17.40 4.28 81.00 0.38 20.17 
56-(MANUKA/NZ) 19.00 NES 79.25 14.51 41.67 
MEAN 18.30 ± 
0.82 
4.36 ± 
0.11 
79.92 ± 0.95 5.29 ± 8.01  
NES-Not Enough Sample for analysis 
 
 
 
 
 
Impurification (%) = 
79 
 
Table 4.2: Physicochemical properties and mean MIC of selected honey samples. 
REFERENCE CODE WATER 
CONTENT 
% 
PH SUGAR 
CONTENT 
% 
% 
IMPURIFIED/ADULTERATED 
MEAN 
MIC 
1–(CITYMIXA/EC) 20.75 4.21 77.50 15.19 17.36 
2-(CITYMIXB/EC) 21.00 4.40 77.50 1.61 30.56 
4-(CITYMIX/EC) 19.50 NES 78.60 0.88 13.89 
5-(CITYMIXTUART/WC) 18.20 4.39 81.80 4.85 50.00 
6-(MANGO/WC) 16.50 4.16 82.00 0.81 30.56 
9-(STRANDVELD/WC) 20.50 4.46 78.00 1.95 28.47 
12-(BUSHVELD/KZN) 20.50 NES 77.50 7.61 14.58 
13-(BUFFALOTHORN/NC) 17.50 4.99 81.00 2.53 25.69 
14-HOOKTHORN/NC) 16.00 4.20 82.50 3.60 50.00 
15-(ONION/WC) 18.00 5.09 80.25 2.34 15.28 
16-(FYNBOS/WC) 18.50 NES 79.50 4.98 10.42 
17-(AKMS/FS) 17.50 4.89 81.00 2.04 14.58 
18-(MIXEDGUM/FS) 16.50 4.20 81.50 0.61 15.97 
19-(CITYMIX/FS) 17.00 4.52 81.25 2.78 11.11 
20-(FORRESTREDGUM/WC) 17.60 4.41 80.60 0.44 17.36 
21-(SUGARGUM/WC) 18.80 4.45 79.00 2.11 30.56 
24-(STRANDVELD/WC) 17.25 4.38 81.25 0.89 25.00 
25-(BUCFYN/WC) 18.25 4.48 79.75 4.42 25.00 
26-(FYNBOS/WC) 18.30 NES 80.00 0.41 20.14 
27-(AEF/WC) 19.00 4.28 79.00 1.09 20.14 
31-(MACADAMIA/WC) 20.50 4.28 78.00 0.19 27.78 
35-(FYNBOSEC/WC) 19.00 4.49 79.25 2.69 26.39 
36-(EUCLADFICI/WC) 18.70 4.35 79.50 1.24 15.97 
37-(FYNBOS/WC) 18.50 4.12 79.50 2.87 26.39 
38-(WASBESSFYNBOS/WC) 18.00 4.36 80.00 0.83 20.14 
40-(FYNBOSGUARRI/WC) 15.80 3.89 82.50 2.30 31.94 
41-(INDIGENOUS/WC) 21.60 4.22 76.75 2.70 13.19 
43-(KARROVELD 19.80 4.06 78.20 3.10 21.53 
44-(STRANDVELD/WC) 19.00 4.79 79.00 1.89 22.92 
45-(FYNBOS/WC) 20.50 4.14 77.50 2.08 20.14 
47-(SALIGNAGUM/KZN) 21.50 4.50 77.00 19.43 50.00 
48-(BRE/EC) 19.00 4.32 79.00 5.50 29.17 
49-(CITRUS/EC) 17.25 4.02 81.25 3.24 45.14 
51-(URBANFORAGE/WC) 18.25 4.65 80.10 1.47 17.36 
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REFERENCE CODE WATER 
CONTENT 
% 
PH SUGAR 
CONTENT 
% 
% 
IMPURIFIED/ADULTERATED 
MEAN 
MIC 
52-(SUBURBANGARDEN/WC) 18.30 NES 80.10 0.41 14.58 
53-(LITCHI/MP) 18.80 NES 79.40 33.60 45.14 
MEAN 18.66 ± 
1.51 
4.39 
±0.28 
79.63 ± 
1.58 
4.02± 6.38  
NES-Not Enough Sample for analysis  
 
4.3.1 Water content 
 
The moisture content of the honey samples tested ranged from 15.80-21.60 with a mean 
moisture content of 18.66 ± 1.51. The limit set by the Codex standard is a maximum of 
20.00% as per European regulations (The Council of European Union, 2002). Of the 36 
samples tested, 8 samples (22.22%) were over the maximum stipulated by the Codex. 
These results were comparable to the results obtained in Southern Africa (10.09%-20.73%) 
(Serem and Bester, 2012), Algeria 14.64%-19.04% (Ouchemoukh et al., 2010) and Morocco 
14.30%-20.20% (Chakir et al., 2011). This demonstrates that moisture content is affected by 
climatic and geographic conditions. Nevertheless, human error during testing or 
condensation may have inadvertently resulted in the addition of water as well.  
The degree of honey maturity as well as the ambient temperature are related to and may 
directly affect the moisture content. Moisture content is a key parameter in the quality 
analysis of honey as fermentation is a concern. Fermentation would be a factor in the 
determination of shelf life of a product as honey fermentation occurs during storage due to 
the activity of osmotolerant yeasts. This results in the formation of ethyl alcohol and carbon 
dioxide. Moisture content is also dependent on factors such as ripening, moisture of the 
nectar and harvesting. Storage conditions of honey may alter the moisture content as a 
result of water transfer (Gomes et al., 2010; Zamora et al., 2010; Chakir et al., 2011) 
Samples with a low moisture content are considered to be of high quality (Voidaroua et al., 
2011). The National Honey Board states that honeys possessing a moisture content less 
than 17.1% will not ferment should the honey be stored appropriately. Air with a relative 
humidity above 60% will allow the absorption of moisture by honey with a moisture content 
of 18.8% or less (Olaitan et al., 2007). Hygroscopicity is defined as the ability to retain water. 
This is an important factor to be considered in the processing and storage of honey. 
Hygroscopicity, in terms of excess water content, may hinder the stability of honey and 
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negatively affect its storage and preservation (Olaitan et al., 2007). It may do so as a high 
water content is a platform for the thriving of potential pathogens.  
4.3.2 pH 
The pH of the samples tested in this study ranged from 3.89-5.09, displaying acidic 
characteristics. The mean pH was 4.39 ± 0.28. A pH measurement could not be obtained for 
six samples as there was a limited quantity of sample. Honey is typically acidic, with a pH 
ranging between 3.2-4.5 (White, 1975). Acidic characteristics impart to honeys antimicrobial 
activity as a low pH inhibits and prevents microbial growth (Shenoy et al., 2012). Gluconic 
acid and inorganic ions in honey are components postulated to contribute to honeys acidic 
nature (Ouchemouk et al 2010). Thus, the pH is a beneficial guide to assessing microbial 
growth. Pathogens usually thrive in a pH of 7.2-7.4 (Molan, 1992). The pH range in the study 
was 3.89 to 5.09, and is therefore low enough to inhibit potential pathogens. These results 
were similar to those reported in a previous SA study where Basson and Grobler (2008) 
reported a pH of approximately 3.6 for the SA honey samples tested (Basson and Grobler, 
2008). Serem and Bester (2012) investigated the pH of honeys from Southern Africa 
including SA and Mozambique and these values ranged from 3.87-5.12 (Serem and Bester, 
2012). Similarly, pH values ranging from 3.50-4.43 were seen in Algeria, a completely 
different geographical region (Ouchemoukh et al., 2010). A study with Moroccan honeys 
revealed pH values of 3.80-4.50 (Malika et al., 2005). These values are similar to findings of 
this study. The pH of honey plays a vital role during the harvesting and storage of honey as 
this parameter will affect the consistency, stability and shelf life (Terrab et al., 2004).  
4.3.3 Sugar content 
The sugar content range was 77.00-82.50%, with a mean sugar content of 79.63±1.58%. 
Honey may act as a desiccant due to its hyperosmolar trait. Due to its large content of solids 
and low moisture content, it draws water from the pathogen thereby destroying it.  Due to the 
supersaturated nature of honey, it leaves very few free water molecules within the 
compound to facilitate thriving of possible pathogens. The sugar present in honey imparts 
characteristics such as viscosity, hygroscopicity, granulation and energy value 
(Ouchemoukh et al., 2010). Sugars help honey to demonstrate antimicrobial activity by 
producing an osmotic effect (Bangroo et al., 2005). Sugar profiles of honey have been 
utilised to differentiate honey type and geographical origin, as the sugar content varies with 
honey type. The sugar content is dependent on the flora the bees forage on and 
geographical weather conditions (Olaitan et al., 2007). Sugar content range in this study was 
77.00-82-50%. This is comparative to a study done on Spanish honeys where the range was 
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78.8%-84.00% (Terrab et al., 2004) and in Algerian honeys where similar ranges of 73.05-
81.38% were observed (Ouchemouk et al., 2010). 
4.3.4 Impurification 
The percentage impurification ranged from 0.19-33.60, with a mean percentage ranging 
between 4.02±6.38%. The main constituents of honey, fructose and glucose, can be 
artificially added to honey to misrepresent the pure honey. Three samples [1–
(CITYMIXA/EC), 47-(SALIGNAGUM/KZN) and 53-(LITCHI/MP)] displayed substantial 
impurification with percentages of 15.19, 19.43 and 33.60 % respectively. When compared 
to the mean percentage impurification of 4.02%, the values were extensive. This confirmed 
the lack of purity of these honey. Furthermore, there are economic ramifications of the 
impurification of honeys and this practise, if deliberate (adulteration), can be regarded as 
unethical and illegal in some countries (Fairchild, 2000).  
Despite the possibility that the above-mentioned physicochemical properties may influence 
antimicrobial activity, no definite correlation confirming this, was observed in this study as 
depicted by the MIC values obtained.  
4.4 Conclusions 
 The moisture content of the SA honey samples tested ranged from 15.80-21.60% 
with a mean moisture content of 18.66 ± 1.51%. 
 The pH of the samples tested in this study ranged from 3.89-5.09 with a mean pH of 
4.39 ± 0.28. 
 The sugar content ranged from 77.00-82.50% with a mean sugar content of 79.63 ± 
1.58%. 
 All 36 samples tested were to some extent impurified with the percentage 
impurification ranging from 0.19-33.60%, with a mean percentage of impurification of 
4.02 ± 6.38%. 
 In this study no correlation could be observed between the physiochemical properties 
and antimicrobial effects of honey despite these factors influencing antimicrobial 
activity in theory.  
 
 
 
 
 
 
83 
 
CHAPTER 5 
CONCLUSION 
 
This study was performed with the aim of validating the antimicrobial efficacy of SA honeys 
in wound infections. The study endeavoured to deliver insight into the potential to utilise SA 
honey as an effective antimicrobial agent in wound healing. Results from this study certainly 
highlighted that selected SA honey samples have noteworthy antimicrobial activity against 
pathogens associated with wound infections. Key focus areas of this research report were 
the antimicrobial properties of various SA honeys, their antimicrobial effects when combined 
with conventional antimicrobials and their physicochemical properties. 
 
5.1 Antimicrobial activity of honey 
 
Evaluation of the potential antimicrobial properties of the various SA honeys from varying 
geographical locations within the country revolved around rigorous in vitro testing. Extensive 
antimicrobial testing against a variety of common wound pathogens was conducted to 
determine the minimum concentration of honey that can successfully inhibit the growth of 
these pathogens tested in this study. Commercially available Manuka honey was utilised as 
a control and antimicrobial activity of these samples ranged from 15.28-41.67%. The mean 
MICs of the SA honey samples tested ranged from 10.42-50.00%. The greatest antimicrobial 
activity was exhibited by honey sample 16-(FYNBOS/WC) which displayed a mean MIC of 
10.42±8.27%.  
 
5.2 Combination studies 
 
Combination studies were undertaken with the aim being to assess and evaluate the 
potential for combining honey, which is a complementary medicine, with conventional 
antimicrobials such as ciprofloxacin, gentamicin and antifungal agents such as amphotericin 
B and nystatin to investigate whether synergism, additive or antagonistic effects were 
observed. Honey displayed noteworthy potential to be combined with antibiotics namely; 
ciprofloxacin and gentamicin and antifungals namely; nystatin to produce synergism. A 
summary of the most synergistic interactions observed are demonstrated in Table 5.1.  
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Table 5.1: The ΣFIC for honey samples displaying synergistic interactions with selected 
allopathic antimicrobials against the respective pathogen tested. 
 
HONEY SAMPLE ANTIBIOTIC PATHOGEN ΣFIC 
18-(MIXEDGUM/FS Ciprofloxacin P. aeruginosa 0.38 
19-(CITYMIX/FS) Ciprofloxacin P. aeruginosa 0.50 
16-(FYNBOS/WC) Gentamicin S. aureus 0.27 
18-(MIXEDGUM/FS) Gentamicin S. aureus 0.27 
19-(CITYMIX/FS) Gentamicin S. aureus 0.27 
26-(FYNBOS/WC) Gentamicin S. aureus 0.27 
41-(INDIGENOUS/WC) Gentamicin S. aureus 0.27 
16-(FYNBOS/WC) Gentamicin P. aeruginosa 0.31 
19-(CITYMIX/FS) Gentamicin P. aeruginosa 0.47 
16-(FYNBOS/WC) Nystatin C. albicans 0.37 
 
5.3 Physicochemical characterisation 
Honey is a complex substance with many constituents which give rise to its physicochemical 
properties. There is limited data on the characterisation of SA honeys, and this study 
afforded insight into some of these properties. The pH of honey samples tested in this study 
ranged from 3.89 to 5.09, displaying acidic characteristics. The sugar content range was 
77.00-82.50%, and the moisture content range was 15.80-21.60%. The 
impurification/adulteration ranged from 0.19-33.60%. Three samples namely; [1–
(CITYMIXA/EC), 47-(SALIGNAGUM/KZN) and 53-(LITCHI/MP)] displayed considerable 
impurification. 
5.4 Recommendations for future studies 
The ideal standardised SA honey with the best antimicrobial activity that can be used for 
therapeutic purposes is the ultimate long-term goal. This could be attained if the data 
obtained from this study and others like this could be incorporated into a design of 
experiments statistical evaluation software tool (i.e. Modde or Simca-P from Umetrics) to 
statistically determine and predict an optimised honey sample with the most desirable 
antimicrobial activity. A statistical analysis catering for all variables will be an undisputed tool 
in determining an optimised, standardised honey. 
 
There is a vast range of floral origin of honey. Pollen analysis should be conducted to verify 
botanical source of honey.  
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Wounds are generally polymicrobial hence a greater sample set of test pathogens should be 
applied. Other examples include species from Corynebacterium, Pityrosporum, Klebsiella, 
Acinetobacter and Stenotrophomonas etc. Similarly, fungal infections are not limited to just 
Candida species. Other problematic fungal species affecting the skin include; Trichophyton 
mentagrophytes and Microsporum canisare which are also important to evaluate. Hence a 
greater microbial and fungal sample set would need to be tested against with the optimised, 
standardised honey to fully elucidate its potential as an antimicrobial and anti-fungal agent. 
 
Future combination studies should include the investigation of a greater number of antibiotic 
agents. A single antibiotic from each class including; penicillins, cephalosporins, 
carbapenams, macrolides, tetracyclines, aminoglycosides, sulphonamides and quinolones 
should be assessed in combination with the optimised honey samples. This will allow for a 
more holistic and accurate determination of honeys combination potential with conventional 
antibiotics, to investigate whether synergism, additive or antagonistic effects are observed to 
enhance and optimise the therapeutic outcome of certain infectious diseases.   
 
There have been in vivo studies on the effectiveness of honey as an antimicrobial agent (El-
Banby et al., 1989; Gupta et al., 1992; Suguna et al., 1992). Despite this, these studies are 
20 years and older and do not include any SA honeys. Further in-vivo studies are required to 
confirm the noteworthy in-vitro results of SA honey and possibly form a correlation. 
 
5.5 Final conclusion 
 
Results from this study highlight the potential for using honey as an effective antimicrobial 
agent. Despite being an in vitro study, this study forms a platform for expanding honey-
based antimicrobial treatment of certain infectious diseases, especially in South Africa. 
Honey as a wound dressing is of particular importance in the South African health care 
setting as a honey would be a favourable dressing for patients in rural areas where there is 
the possibility of infection occurring before first-line medical treatment is obtained. 
Furthermore, to date, there have been no reports of resistance to honey (Blair et al., 2009; 
Cooper et al., 2010). Thus, there is a need for the development of honey dressings and 
similar wound healing products containing honey, particularly in third world countries. The 
cost-effectiveness of honey as either a sole or adjunctive therapeutic agent makes it a 
feasible option for treating certain infections. In addition, the medicinal value attributed to 
selected honey samples examined here, impacts positively on the commercial value of SA 
honey. The value of honey with high therapeutic potential increases, as seen in the case of 
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Manuka honey obtained from New Zealand. Thus, this will have a significant impact on the 
bee keeping industry. In the event of a honey being marketed, SA bee keepers will have a 
competitive edge on the highly stringent global market.  
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Abstract 
 
Background: The therapeutic potential of honey for the treatment of wound infections is well 
documented. However, the difference in antimicrobial potency among various honey types 
can be as large as 100-fold, depending on its geographical and botanical sources. South 
African (SA) honey has been poorly explored as an antimicrobial agent and given the well-
established antimicrobial properties of the indigenous plant species from SA, there is the 
potential that honey from this geographical region may exhibit noteworthy anti-infective 
properties. In this study, the antimicrobial properties of 42 honey samples from eight 
provinces in SA (Eastern Cape, Western Cape, Northern Cape, Kwa-Zulu Natal, Free State, 
Mpumalanga, North West and Limpopo) were determined.  
Methods: The agar dilution method was used to quantify the minimum inhibitory 
concentration (MIC) against various Staphylococcus aureus strains, Pseudomonas 
aeruginosa and two Candida albicans trains. In addition, the physicochemical properties 
including pH and water content were analysed and Stable Isotope Analysis (SIA) was 
performed. 
Results: The study demonstrated that some SA honeys exhibit considerable antimicrobial 
activity. Pseudomonas aeruginosa was generally the most sensitive of the pathogens tested, 
while C. albicans was the least sensitive. The MICs of the honeys ranged from 6.25% to 
50.00%. Samples 4-(CITYMIX/WC), 12-(BUSHVELD/KZN), 15-(ONION/WC), 16-
(FYNBOS/WC), 17-(AKMS/FS), 19-(CITYMIX/FS), 41-(INDIGENOUS/WC) and 52-
(SURBURBANGARDEN/WC) displayed broad-spectrum antimicrobial activity equivalent to 
or better than the commercially obtained manuka honey. The pH of the honeys ranged 
between 3.89 and 5.09, providing some validation for its antimicrobial efficacies. Stable 
isotope analysis (SIA) revealed strong overall trends between protein concentration and MIC 
suggesting close links with antimicrobial activity.  
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Conclusions: The future of South Africa’s market for medical grade and therapeutic honeys 
looks promising, as there is minimal impact of sugar adulteration and the antimicrobial 
properties of the honeys have some superior activity. 
 
Keywords: Wound pathogens; Minimum inhibitory concentration; Agar dilution method; 
Isotope analysis; Protein; Honey; Antimicrobial. 
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